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Abstract 
This thesis focuses on the development of new biocatalytic strategies as a 
contemporary solution to synthetic design. Here we have put to use the unique regio-
, stereo- and/or chemoselectivity offered by biocatalysts to develop synthetically 
attractive routes to enantiopure materials. 
The first chapter discusses the development of a transaminase triggered aza-Michael 
cascade towards the synthesis of enantioenriched 2,6-disubstituted piperidines in 
good yield with >99% e.e. and >99% d.e. This methodology utilises a favourable 
spontaneous intramolecular aza-Michael reaction (IMAMR) to drive the reversible 
enzymatic transformation towards the formation of cyclic products, thus removing 
the need for additional approaches to displace the reaction equilibrium towards 
product formation. The alkaloid, (-)-pinidinone, was synthesised in three steps on a 
0.5 g scale and a range of analogues was also successfully prepared to demonstrate 
the scope of the reaction. The reversible transamination reaction in combination 
with the thermodynamically favourable IMAMR, forming a stable cyclic product, 
results in a regioselective transamination of (3E)-dec-3-ene-2,8-dione. This inspired 
us to develop an amino donor and acceptor substrate that was successfully 
transaminated to form pinidinone with no external source of amine.  
The second chapter discusses the synthesis of novel bis-conjugated enones and their 
subsequent transamination to provide bicyclic alkaloids via double aza-Michael 
additions. However, under the tested reaction conditions, the TA reaction resulted 
in complete decomposition of all but two of the tested substrates. 1-
Methyldecahydropyrrolo[1,2-a]quinolin-5(1H)-one was produced as three isomers 
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whose relative stereochemistry was assigned by NMR. Interestingly, transamination 
of (2E)-1-(cyclohex-1-en-1-yl)oct-2-ene-1,7-dione provided 1-(cyclohex-1-en-1-yl)-2-
[(2S,6S)-6-methylpiperidin-2-yl]ethanone as the major product and an inseparable 
mixture of 1-methyldodecahydro-6H-pyrido[1,2-a]quinolin-6-one isomers as the 
minor product. Initiating the second IMAMR of 1-(cyclohex-1-en-1-yl)-2-[(2S,6S)-6-
methylpiperidin-2-yl]ethanone was attempted. The epimerisation of 1-
methyldecahydropyrrolo[1,2-a]quinolin-5(1H)-one and 1-methyldodecahydro-6H-
pyrido[1,2-a]quinolin-6-one proved unproductive.  
The third chapter investigates the synthesis of 2-alkyl-3-(4-oxopentyl)cyclohex-2-en-
1-one and their subsequent use in a TA-IMAMR cascade towards the pragmatic 
synthesis of the natural product histrionicotoxin (HTX) and its derivatives. A Baylis-
Hillman reaction was optimised for the insertion of the α-alkyl substituent into the 
cyclohexanone scaffolds. TA conditions were found to convert the unsubstituted 
scaffold to provide (2S)-2-methyl-1-azaspiro[5.5]undecan-8-one as a 1:1 mixture of 
diastereoisomers. The optimal epimerisation conditions found provided a 3:1 
mixture of diastereoisomers, however, isolation of the compounds proved 
unsuccessful. Reduction of the carbonyl to provide the core HTX structure was 
tested. This provided an inseparable mixture of products. Under the biocatalytic 
reaction conditions, the IMAMR of 2-ethyl-3-(4-oxopentyl)cyclohex-2-en-1-one 
provided 3-[(4S)-4-aminopentyl]-2-ethylcyclohex-2-en-1-one as the major product. 
This is due to the (2S)-7-ethyl-2-methyl-1-azaspiro[5.5]undecan-8-one being an 
unfavourable product, which is in agreement with current literature.  
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1. Introduction 
1.1 Alkaloids 
The alkaloids are a group of secondary metabolites that contain one or more nitrogen 
atoms, often incorporated into a (hetero)cyclic system(s). Originally, they were 
categorised as occurring predominantly in plant species, however it is now known 
that they are ubiquitous to all terrestrial and marine dwelling organisms. Their 
diverse structures and biological properties have fascinated both chemists and 
biologists, which has led to alkaloids being one of the most intensely investigated  
class of natural products.[1,2] 
Humans have exploited the biological activity of alkaloids for centuries.[1] This 
includes their application as traditional medicines, toxins and the modern day 
substances of abuse: for instance, the well-known alkaloids cocaine and nicotine 
(Figure 1). Natural products are unique in the roles they play in biological systems, in 
which evolution has designed them to bind selectively to proteins such as enzymes 
and receptors. Nature has provided chemists with a catalogue of inherently selective 
scaffolds, which often prove to be leads for potential drug candidates.[3,4] In general, 
nitrogen heterocycles are invaluable to the pharmaceutical industry, appearing in 
59% of FDA approved unique small-molecule drugs.[5] 
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Figure 1: Common natural alkaloids 
In order to perform biological testing of alkaloid natural products, they must be 
isolated in a reasonable quantity. Extraction from the original source is often deemed 
complicated, expensive and can be prohibited due to the protection of an 
endangered species. Biosynthetic pathways to natural products can be derived from 
identifiable amino acids, however, producing these reactions in a laboratory with 
enzymes is far from trivial. Therefore, there is a clear need for the development of 
new synthetic methods to access alkaloid natural products and their derivatives in an 
accessible manner. One of the greatest challenges in total synthesis is to prepare a 
natural product target stereoselectively whilst being applicable on a large scale.[6] To 
this end, organic chemists must endeavour to explore novel asymmetric 
methodologies, for the synthesis of chiral amines, which are the most 
straightforward precursors for these valuable N-containing heterocycles.  
1.2 Asymmetric synthesis of amines via reductive amination 
An effective method for installing chiral amine functionality is via asymmetric 
reductive amination (ARA) of a carbonyl group. This procedure involves the in situ 
formation of an imine and the use of a chemoselective catalyst that can selectively 
reduce the imine to afford the desired amine, whilst circumventing any potential 
carbonyl reduction.[7]  
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The hydrogenation of an imine intermediate utilising transition metal catalysts and 
chiral ligands offers a potential route for performing an ARA, however, the amine 
products can often lead to catalyst poisoning, producing certain limitations.[8] Blaser 
et al. were the first to demonstrate the use of an enantioselective reductive 
amination for the synthesis of (S)-metolachlor (Scheme 1).[9] This methodology 
utilises an iridium catalyst in the presence of a chiral diphosphine ferrocene ligand, 
xyliphos. Zhang et al. expanded the scope of the iridium catalysed hydrogenation of 
imines by using (S,S)-binaphane as the ligand.[10] The addition of the Lewis acid 
titanium isopropyloxide accelerates the formation of the imine, which results in 
complete conversion to the desired chiral amines with ≤ 96% e.e. (Scheme 2).  
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Scheme 1: Synthesis of (S)-metolachlor via asymmetric reductive amination 
 
Scheme 2:  Ir catalysed reductive aminations by Zhang[10] 
Moving away from iridium, in 2000, Borner et al. demonstrated that a chiral rhodium 
(I) catalyst can perform an ARA reaction, diverging from aniline as the amine source 
to the more reactive benzylamine.[11] Their initial results demonstrated moderate 
selectivity between the imine and carbonyl hydrogenation reaction, however, the 
exchange of the achiral ligands dppb and dpoe to a chiral ligand allows for an ARA 
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reaction (Table 1, entry 1). Borner et al. then developed a high-throughput screening 
method, testing 96 chiral phosphorus based ligands, to optimise the rhodium 
catalysed asymmetric reductive amination procedure.[12] The best results are 
achieved with diphenylphosphino ligands (Table 1, entry 2-4), due to the proposed 
formation of five-membered chelate intermediates. 
Table 1: Rhodium catalysed reductive amination developed by Borner[11,12] 
 
Entry Ligand Yield (%) e.e. (%) 
1 
 
59 38 (R) 
2 
 
99 95 (S) 
3 
 
99 91 (R) 
4 
 
98 92 (S) 
 
Inspired by work carried out at Merck on the chemoselective hydrogenation of 
unprotected enamines, in the presence of an amide/ester group,[13] 
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Bunlaksananusorn et al. developed a ruthenium catalysed ARA of β-keto esters.[14] 
The use of a diphenylphosphino ligand results in excellent chemo- and 
stereoselectivity, providing chiral β-amino esters in excellent e.e. and good yield 
(Scheme 3). Later, Merck reported the chemoselective ruthenium catalysed ARA of 
β-keto amides, using ammonium salicylate as the ammonia source (Scheme 3).[15]  
 
Scheme 3: Chemoselective ARA of dicarbonyl substrates by Bunlaksananusorn[14] 
Inspired by the organocatalytic ARA promoted via a cooperative catalyst system of 
Hantzsch esters and a chiral phosphoric acid described by MacMillan et al.[16] and List 
et al.[17] (Scheme 7, Scheme 8), Xiao et al. developed a metal-Brønsted acid 
equivalent.[18] The use of a diamine-ligated iridium catalysts and a phosphoric acid 
provides excellent yield and selectivity in the hydrogenation of acyclic imines across 
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a broad range of substrates. A mechanistic study of this reaction concluded that the 
formation of noncovalent interactions, provides a highly ordered active catalytic 
species, which allows the selective transfer of the hydride ion.[19] The direct ARA of 
carbonyl compounds was then described;[20] where the phosphoric acid has a dual 
catalytic effect, catalysing both the in situ imine formation and its selective reduction. 
The process provides excellent yields and selectivity for a broad range of aromatic 
and aliphatic carbonyl substrates (Scheme 4). 
 
Scheme 4: Cooperative metal-Brønsted acid catalysed ARA 
Finally, Rubio-Pérez et al. employed a palladium species as a catalyst for the ARA of 
ketones (Scheme 5).[21] In contrast to previous reports, the reaction proceeds with 
low selectivity for aromatic ketones, but aliphatic ketones provide very good yields 
and enantioselectivites. Although a wide range of methods have been developed to 
effect by catalytic hydrogenation, the majority of the highlighted processes are 
ineffective or poorly suitable for large-scale preparations. Many of the existing 
methods are superseded by an indirect reductive amination (where the imine species 
must be pre-formed and previously isolated), to circumvent complicated reactions 
and sophisticated metal complexes. To challenge this, Changi et al. demonstrated 
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that an ARA can be utilised as an industrial process, for the synthesis of the 
cholesteryl ester transfer protein inhibitor evacetrapib (Scheme 6).  Their report 
encompasses extensive optimisation via testing of the reaction parameters and the 
development of mathematical models.[22] 
 
Scheme 5: Palladium catalysed ARA 
 
Scheme 6: The utilisation of an ARA for the synthesis of evacetrapib  
An alternative process that avoids the use of expensive and precious metals is the 
organocatalytic ARA. This was first achieved by MacMillan et al.. Their report 
highlights the use of a Hantzsch ester in combination with a modified Akiyama chiral 
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hydrogen-bonding catalyst to provide chiral amines from the corresponding ketones 
(Scheme 7).[16] The formation of water arising from imine condensation has an 
adverse effect on the overall process, hindering the overall imine formation and the 
hydride reduction step. Therefore, the incorporation of 5 Å sieves is deemed vital for 
attaining practical yields and selectivities. 
 
Scheme 7: Organocatalytic ARA of ketones by MacMillan[16] 
In a similar fashion, List et al. developed a procedure for the organocatalytic ARA of 
aldehydes.[17] Using a chiral phosphoric acid as the catalyst, racemic α-branched 
aldehydes - in the presence of p-anisidine and a Hantzsch ester - afford β-branched 
secondary amines in excellent yields and enantioselectivities via an efficient dynamic 
kinetic resolution (Scheme 8). 
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Scheme 8: Asymmetric reductive amination of aldehydes by List 
A Lewis basic formamide (derived from N-methylvaline), in combination with 
trichlorosilane, has also been utilised in an efficient organocatalytic reductive 
amination of α-chloroketones, for the synthesis of chiral aziridines.[23] Trichlorosilane 
is employed to selectively catalyse the reduction of the prochiral N-aryl ketimines 
(Scheme 9A). Benaglia et al.  investigated this methodology further and reported 29 
chiral Lewis bases that provide good catalytic activity in this process.[24] Using their 
most selective catalyst the synthesis of (S)-metachlor was achieved in comparable 
selectivity and yield to the iridium catalysed methodology by Blaser et al. (Scheme 
9B). Jones et al. reported that pre-formed imines, synthesised from aliphatic amines 
via microwave irradiation, can subsequently be reduced with a chiral Lewis base and 
trichlorosilane. This methodology has been applied to the synthesis of the 
calcimimetic drug, (R)-(+)-NPS R-568 (Scheme 9C).[25] 
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Scheme 9: Organocatalysed reductive amination with trichlorosilane 
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1.3 ω-Transaminases in synthesis: Biocatalytic reductive 
amination 
Recent publications have demonstrated the use of biocatalysis to insert chiral amine 
functionality, supplementing the existing organo- and transition metal-based 
catalytic methodologies.[26] Biocatalysts can perform a number of transformations 
with levels of regio-, stereo- and/or chemoselectivity that current chemo-catalysts 
cannot achieve. This has led to the concept of “biocatalytic retrosynthesis”,[27] which 
provides a variety of new tools to approach certain synthetic disconnections and 
functional group interconversions that were previously implausible.  
In particular, transaminase (TA) enzymes are of significant interest due to their ability 
to catalyse the reversible reaction between a prochiral carbonyl compound (amino 
acceptor) and an amine source (amino donor), in the presence of its cofactor 
pyridoxal-5′-phosphate (PLP), to form the desired chiral amine with both high stereo- 
and regioselectivity. The use of the α-TA family as catalysts for the synthesis of chiral 
α-amino acids, is a well establish process, however ω-TA have only recently been 
highlighted for their ability to also catalyse reactions with ketone and aldehyde 
functionalities.[28] Celgene was the pioneering biopharmaceutical company to report 
the use of (R)- and (S)- selective ω-TA for the production of chiral amines via both a 
kinetic resolution of a racemic amine mixture (Scheme 10A) and the enantioselective 
synthesis of amines from prochiral ketones (Scheme 10B).[29] 
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Scheme 10: Transaminase utility in the production of chiral amines 
The reaction proceeds via the cofactor PLP that undergoes a reversible prototropic 
tautomerization followed by hydrolysis with an amino group to form the 
intermediate pyridoxalamine (PMP), effectively acting as a transport for the amine 
group and electrons between amine donor and acceptor (Scheme 11). 
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Scheme 11: The reaction mechanism of the cofactor PLP with amines and carbonyls 
within a ω-TA active site. 
A major obstacle in the use of TAs as catalysts for the production of chiral amines is 
that the reaction thermodynamics are often unfavourable. However, troublesome 
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reaction equilibria can be overcome by, for example, the removal of the carbonyl co-
product formed upon transamination. Thus, in large scale reactions, the use of an 
excess of isopropylamine as amine donor, and in-situ evaporation of acetone co-
product, drives the equilibrium towards the desired chiral amine product. 
Industrially, this approach is very effective for some substrates, although technically 
challenging, as the concentration of isopropyl amine has to be closely controlled 
(typically under 1 M) to prevent adverse effects on the TA (Scheme 12A).[30] An 
alternative approach to displace the equilibrium towards the desired amine, which is 
commonly applied for small-scale reactions, consists of the use of L-alanine as amine 
donor in combination with a pyruvate removal co-enzyme (Scheme 12B). Although 
this provides an elegant way to drive reaction equilibrium, coenzymes are often 
expensive and the possibility of them causing undesired side reactions hinders their 
use in large-scale reactions.[31,32] 
 
Scheme 12: A) In situ acetone removal technique, B) Pyruvate removal system 
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The recently reported synthesis of the anti-diabetic sitagliptin demonstrates how 
biocatalysis can now compete with contemporary chemocatalytic procedures.[33] The 
traditional synthesis of sitaglipin, reported by Merk Pharmaceuticals in 2009, consists 
of the hydrogenation of the enamine derivative from the dicarbonyl intermediate 
(Scheme 13). A rhodium catalyst with a bulky Josiphos diphosphine ligand, under high 
hydrogen pressure, allows the formation of the desired chiral amine in 97% e.e. after 
recrystallisation.  
In contrast, the biocatalytic strategy developed by Codexis and Merck (Scheme 13) 
involves the use of an engineered enzyme (produced after 27 rounds of mutagenesis 
from a wild-type TA) that was capable of accepting the bulky/bulky-substituted 
dicarbonyl.[34] This biotransformation route provides a more economical and safer 
approach by removing the need for an expensive high-pressure hydrogen reactor and 
toxic and expensive rhodium catalyst and ligand. The biocatalytic methodology 
provides an approximate 10-13% increased overall yield, 53% increase in productivity 
(kg L-1) and a 19% decrease in total waste. This remarkable outcome received the 
Presidential Green Chemistry Award in 2010, and in 2012, the Food and Drug 
Administration (FDA) approved the biocatalytic synthesis of sitagliptin.   
17 
 
Scheme 13: Chemocatalytic vs enzymatic synthesis of sitagliptin 
1.4 TA applications for the synthesis of chiral alkaloids 
Turner was the first to report the incorporation of TA enzymes as part of a cascade 
process, utilising a keto-ester system where, upon transamination, spontaneous 
lactamisation occurs, allowing access to a variety of chiral lactam products in 
excellent e.e. (Scheme 14A).[35] The irreversable spontaneous cyclisation provides an 
equillibrium drive towards the formation of the desired product, negating the need 
for a pyruvate removal system. Additionally, TA enzymes can often be inhibited by 
high concentration of starting materials and reaction products, which can occupy the 
enzyme’s active site, reducing the catalytic turnover and, therefore, hampering the 
implementation of these procedures on a preparative/industrial scale. However, the 
spontaneous cyclisation of the amine product helps to overcome this obstacle, 
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making the methodology suitable on a 50 g/L scale, therefore deemed suitable as an 
industrial process. 
This methodology was then elegantly applied to access a range of biological relevant 
molecules, a collection of γ-aminobutyric acid (GABA) derivatives, in a dynamic 
kinetic resolution (Scheme 14B). When Kroutil subjected 4-oxo-3-phenylbutyric acid 
ethyl ester to an (R)-selective ω-TA, the enzyme displayed a preferential selectivity 
towards one of the enantiomers to undergo transamination and subsequent 
cyclisation.[36] As the substrate readily racemised, over a period of time, all of the 
starting material was converted and a good e.e. was observed in all the GABA 
products (Scheme 14B). 
Scheme 14: Spontaneous lactamisation towards chiral products 
The ensuing example highlights the excellent regioselectivity of ω-TA enzymes 
(Scheme 15).[37] This two step synthesis of 2,6-disubstituted piperidines, developed 
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by Kroutil, involves the selective conversion of a single ketone group in a number of 
diketone substrates. Exposure of these substrates to either an (R) or (S) – selective 
ω-TA converts the least hindered keto site, with complete selectivity, into the 
corresponding chiral amine intermediates, providing the corresponding enantiopure 
cyclic imines upon spontaneous cyclisation. These imines can then be isolated and 
selectively reduced in a syn or anti manner to all four diastereomers of the desired 
2,6-disubstituted piperidines (Scheme 15). 
 
Scheme 15: Two-pot TA method for the synthesis of piperidines 
Turner et al. have also reported an elegant multi enzyme one-pot reductive system, 
utilising a selective monoamine oxidase (MAO) in combination with a non-selective 
ammonia borane reduction system, to generate chiral pyrrolidines with excellent 
enantio- and diastereoselectivity (>94% e.e. and >98% d.e.).[38] The report highlights 
how a multienzyme cascade can work in complete synergy, having no adverse effect 
on the regio- and stereoselectivity of the corresponding enzyme (Scheme 16).  
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Scheme 16: One-pot TA method for the synthesis of pyrrolidines 
The most recent report on the topic, highlights both the excellent regioselectivity and 
the ability for enzymes to accept bulky and complex unnatural substrates (Scheme 
17).[39] The triketone substrate undergoes selective monoamination and subsequent 
condensation to form the expected enantioriched pyrroline. Aromatisation of the 
pyrroline with catalytic acetic acid provides the corresponding pyrrole. Again, the 
selective reduction of either the pyrroline or the pyrrole systems provides the 
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corresponding syn or anti products, allowing access to four isomers of the natural 
product xenovenine, a venom isolated from ants and amphibians. 
Scheme 17: Bio-catalysed synthesis of xenovenine  
1.5 Intramolecular aza-Michael reaction (IMAMR) 
The intramolecular aza-Michael reaction (IMAMR) is one of the most commonly used 
methods for generating chiral alkaloids.[40] This class of reaction involves the 
arrangement of a nitrogen nucleophile within close proximity to an electron deficient 
double bond. Until this point, there have been no reports demonstrating the use of 
a biocatalyst to insert amine functionality followed by an IMAMR. Previous 
traditional synthetic methods for performing an IMAMR rely on the synthesis of 
appropriate precursors, where either a deprotection of the nitrogen or the activation 
of the α,β-unsaturated system promotes the formation from the desired carbon-
nitrogen bond. To induce an enantioselective addition, a chiral catalyst or a chiral 
nitrogen nucleophile can be employed.[41] 
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As an example of a traditional method using a non-selective reduction, Stockman et 
al. established a fascinating tandem double intramolecular Michael reaction 
methodology towards the synthesis of an assortment of quinolizidine[42] and 
pyrrolizidine alkaloids (Scheme 17).[43] Interestingly, the IMAMR proceeded with 
relative stereocontrol. For the quinolizidine series, a 2,6-cis-configuration is the 
thermodynamic intermediate, due to the large side chains preferring the equatorial 
positions. The second addition, again controlled by thermodynamics, arranges the 
system into a 4,6-trans-configuration, due to the cis-configuration suffering of steric 
clashes. The pyrrolizidine series however, proceeds through a 2,5-trans-intermediate 
that allows the formation of cis- products. 
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Scheme 17: Tandem reductive amination/double IMAMR 
The enantioselective synthesis of (+)-pelletierine and ()-pinidinol has been achieved 
via an asymmetric IMAMR utilising chiral N-sulfinyl amines as the nitrogen 
nucleophile (Scheme 18).[44] In this report, del Pozo et al. describe the use of sufinyl 
chiral auxiliaries. For the synthesis of ()-pinidinol, the N-sulfinyl amine allows a 
stereoselective addition of the Grignard.[45] In the presence of potassium tert-
butoxide at 40 °C, the IMAMR proceeds with good selectivity, providing a novel 
route to chiral piperidines.  
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Scheme 18: N-sulfinyl chiral auxiliary for the synthesis of chiral piperidines 
Fustero et al. have shown, in the synthesis of (±)-hippodamine, that the N-sulfinyl 
chiral auxiliary can be used in a similar fashion to Stockman et al. (Scheme 17). The 
N-sulfinyl chiral auxiliary allows the first IMAMR to proceed selectively with 92% e.e. 
Separation of the diastereoisomers by flash column chromatography, followed by the 
removal of the N-sulfinyl group, allows the second IMAMR to occur, resulting in the 
formation of the enantiopure quinolizidine (Scheme 19). Subsequent 
transformations allow access to enantiopure ()-hippodamine and (+)-epi-
hippodamine.[46] 
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Scheme 19: Double IMAMR utilising an N-sulfinyl chiral auxiliary 
The use of readily available chiral starting materials is also a useful way to perform a 
diastereoselective IMAMR. In this way, Ma et al. have synthesised three natural 
products from the protected chiral amino alcohol (Scheme 20).[47] The report 
highlights that the stereo outcome of the IMAMR was greatly determined by the 
substituents on the piperidine ring. 
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Scheme 20: Diastereoselective IMAMR of a functionalised piperidine ring 
Hong et al. have shown that Jørgensen's pyrrolidine is able to catalyse the IMAMR 
(Scheme 21).[48] The (S)-pyrrolidine catalyst provides the cis product in a 20:1 d.r., 
due to the transition state having a complementary alignment, with the bulky 
pyrrolidine substituent pointing away from the tosylate group. In contrast, the (R)-
pyrrolidine catalyst points towards the tosylate group, producing an unfavourable 
transition state, which results in a drop to a 4:1 d.r. (Scheme 21). However, this 
organocatalysed IMAMR allows the access to both ()-epimyrtine and (+)-myrtine. 
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Scheme 21: Jørgensen's pyrrolidine catalysts for the diastereoselective IMAMR 
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2. Biocatalytic Preparation of Chiral Piperidines 
The research described in this chapter has been published: J. Ryan, M. Siauciulis, A. 
Gomm, B. Macia, E. O’Reilly, V. Caprio, J. Am. Chem. Soc. 2016, 138, 15798-15800. 
2.1 Introduction 
The piperidine, 6-membered nitrogen saturated heterocycle, is arguably one of the 
most observed scaffolds in natural products and is occurring more and more in 
potential drug candidates.[5] A recent report[49] highlighted that a simple survey of 
the word “piperidine” on the SciFinder search engine produced 93,984 references in 
October 2015 and 97,972 references in January 2017. The increase in almost 4,000 
additional publications over two years proves how much attention this basic 
heterocycle has received. A search on the chemical abstracts service corroborates 
the above analysis by identifying piperidine as the most common heterocycle.[50] 
Of particular interest to our group are the piperidine-based natural products that 
contain a 2,6-cis-disubstituted pattern; lupetidine,[51] dihydropinidine,[52] solenopsin 
A,[51] cassine,[53] spectaline,[54] pinidinol and pinidinone[55] are examples of 2,6-
disubstituted piperidines bearing a 2-methyl substituent and exhibit antifeedant 
properties (Scheme 22). 
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Scheme 22: Examples of natural products containing a 2,6-disubstituted piperidine 
motif 
Amongst the naturally occurring 2,6-disubstituted piperidines, the alkaloid ()-
pinidinone (1a) is found in pine and spruce trees indigenous to the Americas.[55] It 
can also be extracted from the Australian ladybug beetle (Cryptolaemus 
montrouzieri)[56] and the Mexican bean beetle (Epilachna varivestis).[57] It is a 
defensive alkaloid, adversely affecting predators upon consumption. Its asymmetric 
synthesis has been achieved through several routes, which often involve complex 
and long protecting/de-protecting strategies (approx. average of 10 steps) with poor 
overall yields (see example in Scheme 23).[58–63] 
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Scheme 23: Asymmetric synthesis of ()-pinidinone in 10 linear steps[62] 
2.2 Aims and objectives 
Herein we propose a novel methodology utilising TA enzymes to insert a chiral amine 
functionality that will then undergo an IMAMR as summarised in the retrosynthesis 
of ()-pinidinone (1a) (R = Me) (Scheme 24). This methodology will allow access to 
both enantiomers of pinidinone (1a) and a number of non-natural 2,6-disubstituted 
piperidine derivatives. 
 
Scheme 24: Biocatalytic retrosynthetic analysis of ()-pinidinone 
To achieve this, a number of keto-enone substrates 3 where R comprises a broad 
range of functionalities are synthesised. Optimisation of a key biocatalytic 
transformation step of 3 utilising industrially available ω-TA enzymes are tested. The 
final products are fully characterised to determine their absolute stereochemistry.  
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2.3 Substrate synthesis: Ketoenones 3a-e 
Synthesis of a few of our desired keto-enone substrates 3 have previously been 
described by the oxidative ring opening of 1-methylcyclopentene (4) by ozone.[64] 
Looking for an alternative procedure that avoided the ozonolysis reaction, we 
performed the oxidative ring opening of 4 using osmium tetroxide and sodium 
periodate (Lemieux–Johnson oxidation),[65] which provided 5-oxo-hexanal (5) in 85% 
yield, with no purification required (Scheme 25). Next, the Wittig olefination of 5 with 
a range of phosphorus ylids 6a-e, provided the target ketoenones 3a-e in good yield 
(Table 2). 
 
Scheme 25: Synthesis of target ketoenone substrates 3a-e 
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Table 2: Wittig olefination reaction of 5a 
Entry R Product Yield (%)a 
1 Me 3a 79 
2 tBu 3b 58b 
3 
 
3c 57 
4 Ph 3d 76 
5 OEt 3e 66 
a Isolated yield after flash chromatography. b Reaction 
carried out under reflux. 
 
An ideal synthesis would avoid the use of the expensive and toxic osmium catalyst. 
Therefore, we endeavoured to synthesise the keto-enone 3a-e in a sustainable 
manner, based on the commercially available reagent ethyl acetoacetate (7) and 
acrolein (8) (Scheme 26). We envisaged that, in the presence of an appropriate 
catalyst, the two reagents would undergo a Michael addition to provide the Michael 
adduct 9. Torregiani et al. have reported a solvent free reaction using a cerium 
catalyst to produce 9 in 95% yield.[66] In a different study, Sanjay et al. reported the 
Michael addition reaction of 7 and 8 to provide compound 9 in 95% yield, using 
neutral alumina as catalyst.[67] However, both the methodologies have been reported 
on a 1 mmol scale, and the scaling up to a 10 mmol scale proved inadequate in both 
cases (Table 3, entry 1 & 2). Increasing the amount of neutral alumina to 4 eq 
provides a conversion of 77% (Table 3, entry 3). A screening of different amounts of 
basic alumina as catalyst provided lower conversions in all cases (Table 3, entry 4-6). 
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Scheme 26: Alternative synthetic route to ketoenone 3d 
Table 3: Base catalysed Michael addition of acrolein (8) and ethylacetoacetate (7)a 
Entry Catalyst  Catalyst (eq.) Time (min) % Conversionb 
1 Cerium Heptahydrate 0.2 24 h n.d 
2 Neutral Alumina 0.2 10 10 
3 Neutral Alumina 0.4 10 77 
4 Basic Alumina 0.2 10 n.d 
5 Basic Alumina 0.4 10 33 
6 Basic Alumina 0.4 30 20 
a 7 (1.0 eq), 8 (1.1 eq), 0 oC, neat. b Conversion determined by 1H NMR 
 
The Wittig olefination of the crude mixture 9 with 6d, in CHCl3 as solvent at room 
temperature, provided compound 10d in 38% yield after 12 h (Scheme 26). The final 
step of this synthetic strategy consisted on the Krapcho decarboxylation[68] of 
compound 10d, which provided the target compound 3d in 25% yield (Scheme 26). 
Overall, this route proved troubling and unviable on a synthetically useful scale due 
to low yields.  
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2.4 Transamination of ketoenones 3a-e and epimerisation of 
resulting 2,6-disubstituted piperidines 
The work of Turner et al. outlined in Scheme 16 utilises two commercially available 
ω-TA biocatalysts from Codexis (ATA-(S)-113 and ATA-(R)-117), which having 
complementary selectivity, have proved to be apt catalysts for the transamination 
reaction of dicarbonyl substrates.[38] We decided to start our investigations using this 
set of enzymes. Initial amine donor screening displayed exceptional conversions with 
IPA and, after optimisation across our substrate scope, two equivalents of the amine 
donor were found to be optimal, although in some cases only one equivalent of IPA 
was required (Table 5, entry 1a). This methodology seems to contradict the known 
reversibility of TA reactions, as discussed in chapter 1.3. We attribute the excellent 
conversions with low quantities of amine donor to the favourable IMAMR, which 
provides a thermodynamic sink by driving the reaction towards the formation of the 
corresponding cyclic products.  
 
Scheme 27: Transamination of keto-enones 3a-e 
Under our optimised biocatalytic reaction conditions, the IMAMR provided 
approximately a 2:1 ratio in favour of the cis-configuration over the trans-isomer for 
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all the substrates. Isolation of the trans-isomer by column chromatography proved 
unsuccessful for all the substrates, as the C-2 of the piperidine ring readily epimerises 
on silica gel. Therefore, following previous reports,[58] dissolving the corresponding 
crude reaction mixtures in methanol, allowed the 2,6-disubstituted piperidines 1a-e 
to undergo a retro-Michael addition and subsequent IMAMR, resulting in the 
exclusive formation of the cis-isomer, which is approximately 3.8 kcal mol-1 more 
stable than the trans-piperidine (Scheme 28).[69] The relative stereochemistry of all 
the synthesised piperidines was confirmed by 2D-NMR experiments. For example, 
the COSY spectrum of ()-pinidinone showed no coupling between HA and HB (Figure 
2A) while its NOESY spectrum revealed a clear coupling between HA and HB, indicating 
an interaction across space between those protons (i.e. cis configuration) (Figure 2B).  
 
Scheme 28: Epimerisation of carbon 2 in piperidines 1a-e.  
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Table 4: Epimerisation conditions of carbon 2 in piperidines 1a-e 
Entry R Product Temp. (oC) Solvent Time (h) 
1 Me 1a r.t. MeOH 48 
2 tBu 1b 65 MeOH 24 
3 
 
1c r.t. MeOH 48 
4 Ph 1d r.t. MeOH 48 
5 EtO 1e 80 EtOH 24 
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Figure 2: COESY/NOESY analysis for the determination of stereochemistry of 
pinidinone 1a 
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Utilising the optimised conditions, with ATA113 and ATA117, pinidinone (1a) was 
isolated in good yield (Table 5, entry 1 and 2). We then tested a range of non-natural 
equivalents of pinidinone to demonstrate the scope of the methodology. The bulky 
tBu compound 3b was readily converted with ATA113 (Table 5, entry 3); however, 
with ATA117 an extended reaction time was required (Table 5, entry 4). An extended 
alkyne chain 3c, offering the opportunity of further functionalisation, again provided 
excellent isolated yields (Table 5, entry 5 and 6). The aromatic equivalent 3d was 
insoluble in the aqueous reaction medium, however, as long as the enzyme readily 
converts the substrate, full conversion of starting material can be achieved. ATA113 
provided full conversion after 24 h, indicating 3d is an ideal substrate for this enzyme 
(Table 5, entry 7). In contrast, ATA117 only provided a 50% conversion of substrate, 
which shows that 3d is not as readily accepted for this enzyme (Table 5, entry 8). To 
demonstrate further functional groups that can be tolerated by this methodology, 
the ester 3e was examined. This was smoothly converted with the optimised reaction 
conditions (Table 5, entry 9 and 10). To highlight the synthetic utility of the developed 
methodology, we decided to scale up the reaction for the natural product ()-
pinidinone 1a. The scaling up of the reaction by seven fold allowed the synthesis of 
0.48 g of ()-pinidinone 1a with no adverse effects on the conversion, yield, e.e. or 
d.e. of the reaction.  
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Table 5: Substrate screening of 3a-e 
 
Entry R ω-TA Conv (%)a ee (%)b de (%)c Yield (%)d 
1 1a ATA113 >99 >99 >99 91 (S,S) 
2 1a ATA117 >99 >99 >99 90 (R,R) 
3 1b ATA113 >99e >99 >99f 78 (S,S)g 
4 1b ATA117 >99e >99 >99f 88 (R,R)g 
5 1c ATA113 >99 >99 >99 92 (S,S)g 
6 1ch ATA117 >99e >99 >99 90 (R,R)g 
7 1d ATA113 >99 >99 >99 76 (S,S)g 
8 1dh ATA117 50e >99 >99 44 (R,R)g 
9 1e ATA113 >99 >99 >99i 72 (S.S)g 
10 1e ATA117 >99 >99 >99i 70 (R,R)g 
a Conversion determined by 1H NMR after 24 h. b ee determined by chiral GC or 
HPLC. c de determined by NMR after the epimerization step. d Isolated yield after 
flash chromatography. e Conversion after 48 h. f Epimerization was carried out at 
65 oC for 24 h. g Configuration assigned by analogy with 1a and in agreement with 
NOESY experiments. h 4 eq of isopropylamine were used. i Epimerization was 
carried out in EtOH at 80 oC for 24 h. 
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When considering regioselectivity issues in the assayed commercial enzymes, it is 
worth paying special attention to the biocatalysed TA reaction of substrate 3a, which 
displays a clear preference between the two present methyl ketones. The enzymes 
are able to accept readily both of the carbonyls (Scheme 29, reaction A or B), 
however, only pinidinone (1a) is observed (Scheme 29, reaction A). We propose that 
reaction B does occur to from 11a, however, this subsequently undergoes a further 
transamination to either reform the diketone 3a (reaction B) or afford diamine 12a 
(reaction C). Eventually, reaction A or D will occur to form 2a and the spontaneous 
IMAMR will drive the reaction towards the formation of product 1a. To prove our 
hypothesis we decided to synthesise the conjugated aminoketone substrate 11a and 
subject it to a TA reaction with no external source of amine (Scheme 29).I This 
provided full conversion of the starting material to pinidinone (1a). To our 
knowledge, this is also the first example of an internal amine source, as the only 
amine source, being transported across a molecular framework in a TA reaction 
resulting in the first donorless transamination process. 
                                                     
I This work by Andrew Gomm and Mindaugas Šiaučiulis was carried out at the 
University of Nottingham under the supervision of Dr E. O’Reilly 
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Scheme 29: Proposed transamination of diketone 3a and ketoamine 11a to 
pinidinone (1a) 
After identifying that the IMAMR induced a regio-control of the reaction, we were 
interested to see if we could potentially reverse the regioselectivity of the TA reaction 
in favour of a bulkier ketone than a methyl ketone. Synthesis of the ethylketo-
methylenone 3f was achieved utilising 1-ethylcyclopentene and the appropriate 
Wittig reagent 6a following the original procedure. Initial studies on the biocatalysed 
transamination showed poor conversion when ATA-(S)-113 was employed as catalyst 
at room temperature or 30 oC. Fortunately, the use of the Codexis enzyme ATA-(S)-
256 at 50 °C, in the presence of two equivalent of IPA, allowed full conversion of all 
the starting material (Scheme 30). Identification of the Michael cyclic product 1f 
demonstrates a clear example of the IMAMR controlling the regioselectivity of the 
reaction. Piperidine 1f was obtained in 70% e.e., lower enantioselectivity in 
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comparison to the methyl ketoenones 3a-e; we attribute this to the fact that the 
commercially available enzyme ATA256 is heavily engineered towards 
methylketones and that a higher enantioselectivity of the reaction could be achieved 
with an enzyme with a bulky-bulky accepting active site. 
 
Scheme 30: Transamination of an ethylketone in the presence of a methylketone  
2.5 Conclusion 
In conclusion, we have developed an extremely efficient biocatalytic aza-Michael 
strategy for the enantioselective synthesis of 2,6-disubstituted piperidines from 
prochiral ketoenones, with excellent conversion, isolated yield, e.e. and d.e. Our 
approach reveals that tethering a ω-TA biocatalysed amination reaction with the 
strong thermodynamic driving force of an IMAMR, allows the use of very low 
amounts of amine donor (sometimes stoichiometric amounts of IPA are enough to 
reach full conversion) and therefore bypassing the need of a supplementary 
equilibrium driving method. In addition, we have utilised the IMAMR to influence the 
regioselectivity of the TA reaction and demonstrated the first example of an amine 
functionality being transported across a molecular framework to form the desired 
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product. This work significantly expands the scope of ω-TA methodology in total 
synthesis and offers the biocatalytic retrosynthetic route for the synthesis of more 
complex alkaloid scaffolds. 
2.6 Experimental  
General Methods and Materials 
General: NMR spectra were recorded on a JEOL ECS 400 NMR spectrometer (1H 400 
MHz, and 13C 100 MHz). The chemical shifts were recorded in ppm with the residual 
CHCl3 signal referenced to 7.26 ppm and 77.00 ppm for 1H and 13C respectively. 
Coupling constants (J) are reported in Hz, are corrected and refer to the apparent 
peak multiplicities. Thin layer chromatography was performed on Alfa Aesar silica gel 
60 F254 plates. Flash column chromatography was performed on silica gel (60 Å, 230-
400 mesh). GC-MS spectra were recorded on a HP 5973, HP-5MS (30 m  0.25 mm  
0.25 μm), Helium carrier gas, flow 1 mL/min. Infrared spectra were recorded using a 
Thermo Nicolet 380 FT-IR. GC-FID analysis was performed on Agilent 6850 equipped 
with a CP CHIRASIL-DEX CB (25 m  0.25 mm) DF = 0.25 column. HPLC analysis was 
performed on an Agilent 1100 series equipped with a Lux Amylose-1 chiral column 
from Phenomenex. All racemic standards were prepared by mixing equimolar 
quantities of enantiomerically pure biotransformation products. 
Materials: Commercially available reagents, purchased from Sigma Aldrich or Acros, 
were used throughout without further purification. Anhydrous THF, CH2Cl2, diethyl 
ether and toluene were obtained from a Pure Solvent apparatus. Commercially 
available transaminases, ATA113 and ATA117 were purchased from Codexis in the 
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form of lyophilised cell extract. All biotransformations were carried out in HEPES 
buffer (100 mM, pH 7.5) at 30 ºC. 
1-phenyl-2-(triphenylphosphanylidene)ethanone[65] 
To a solution of triphenylphosphine (7.9 g, 30.14 mmol) in CH2Cl2 
(20 mL), 2-bromoacetophenone (5 g, 25.12 mmol) was added and 
the mixture was stirred for 24 h. Diethyl ether (100 mL) was then added and stirred 
for a further hour. The resulting precipitate was suspended in a mixture of 
water/methanol (100 mL, 1:1) and stirred for 1 h. Next, aqueous NaOH (2 M) was 
added until pH 7-8 was reached and the mixture was stirred for 5 h at r.t. Methanol 
was then removed under reduced pressure and the aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic extracts were then dried over Na2SO4, 
filtered and concentrated under reduced pressure to provide the title compound as 
a white solid (9.03 g, 94% yield). 1H NMR (400 MHz, CDCl3): δ 8.02-7.91 (m, 2H), 7.78-
7.65 (m, 6H), 7.60-7.42 (m, 9H), 7.40-7.28 (m, 3H), 4.43 (d, J = 24.7 Hz, 1H). In 
accordance with literature data. 
3,3-dimethyl-1-(triphenylphosphoranylidene)-2-butanone[70] 
To a solution of triphenylphosphine (9.7 g, 37 mmol) in toluene (50 
mL), 1-bromo-3,3-dimethylbutan-2-one (5 mL, 37 mmol) was added 
and the mixture was refluxed for 4 h. The solid precipitate was filtered and washed 
with diethyl ether (3  100 mL). The phosphonium salt was then dissolved in the 
minimal amount of water/CH2Cl2 (1.5:1) and NaOH (2M, 100 mL) was added and the 
mixture stirred for 2 h. The reaction mixture was extracted with CH2Cl2 (3  100 mL) 
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and washed with brine (300 mL), dried over Na2SO4, filtered and concentrated under 
reduced pressure to provide the title compound as a beige solid (10.58 g, 79% yield). 
1H NMR (400 MHz, CDCl3): δ 7.68-7.57 (m, 6H), 7.56-7.47 (m, 3H), 7.47-7.38 (m, 6H), 
3.77 (d, J = 27.0 Hz, 1H), 1.20 (s, 9H). In accordance with literature data. 
1-(triphenylphosphoranylidene)-5-hexen-2-one[71] 
To a solution of 1-(triphenylphosphoranylidene)-2-propanone (1.00 
g, 3.14 mmol) in dry THF (50 mL), n-BuLi (1.9 mL, 2.5 M in hexanes) 
was added at 60°C and the mixture was stirred for 30 min. Excess of allylbromide 
(1.9 mL, 22.0 mmol) was then added and the reaction left to warm to room 
temperature slowly. The reaction mixture was quenched with water (100 mL) and 
extracted was CH2Cl2 (3  100 mL), washed with brine (300 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure to provide the title compound as 
a yellow oil (990 mg, 88% yield). 1H NMR (400 MHz, CDCl3): δ 7.68-7.59 (m, 6H), 7.59-
7.51 (m, 3H), 7.49-7.41 (m, 6H), 5.99-5.83 (m, 1H), 5.11-4.92 (m, 2H), 3.71 (d, J = 26.6 
Hz, 1H), 2.48-2.36 (m, 4H). In accordance with literature data. 
Preparation of conjugated substrates 3a-f 
1-ethylcyclopentene[72] 
Ethyl magnesium bromide (1.2 eq, 48 mmol, 16 mL, 3 M in Et2O) was added 
to cyclopentanone (1 eq, 40 mmol, 3.54 mL) in Et2O (40 mL) under nitrogen 
at 0 °C. The mixture was then allowed to warm to room temperature and stirred for 
a further 2 h. The reaction mixture was then carefully quenched with cold water 
followed by sat. NH4.Cl. The organic phase was separated and the aqueous layer 
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extracted with Et2O (2  40 mL). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated under reduced pressure to provide the crude 1-
ethylcyclopentanol (3.90 g, 86% yield). To this crude material, 85% wt. phosphoric 
acid (0.05 eq, 1.71 mmol, 0.20 mL) was added and the mixture was heated to 115 °C. 
The product was distilled off as it formed and the biphasic solution was separated to 
provide crude 1-ethylcyclopentene as a colourless oil (1.84 g, 48% yield). 1H NMR 
(400 MHz, CDCl3): δ 5.35-5.29 (1H, m, 2-H), 2.35-2.26 (2H, m, 3-H), 2.26-2.19 (2H, m, 
5-H), 2.11-2.02 (2H, m, 1’-H), 1.91-1.80 (2H, m, 4-H), 1.04 (3H, t, J = 7.3 Hz, 2’-H). In 
accordance with literature data. 
General Procedure for Oxidative Ring Opening of 1-methyl- and 1-
ethylcyclopentene 
The corresponding 1-alkylcyclopentene (1 eq, 16.6 mmol) and OsO4 (4% w.t/v tBuOH, 
0.01 eq, 0.17 mmol, 1.06 mL) were added to a solution of N-methylmorpholine N-
oxide (2 eq, 33.2 mmol, 3.89 g) in acetone (20 mL). The mixture was stirred at room 
temperature for 4 h and then quenched with sat. Na2SO3 solution (80 mL) and 
extracted with CH2Cl2 (3  60 mL). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude material was 
dissolved in water (20 mL) and sodium periodate (2 eq, 33.2 mmol, 7.10 g) was 
added. The resulting mixture was stirred for 1 h at room temperature and then 
diluted with water (60 mL) and extracted with CH2Cl2 (3 x 30 mL). Next, the combined 
organic extracts were dried over Na2SO4, filtered and concentrated under reduced 
pressure to provide the desired aldehyde. 
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5-oxo-hexanal (5a)[73] 
Colourless oil (460 mg, 85% yield). FTIR (neat) Vmax: 2941, 2729, 1709, 
1369, 1162 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.75 (1H, s, 1-H), 2.55-2.45 
(4H, m, 2,4-H), 2.13 (3H, s, 6-H), 1.93-1.83 (2H, m, 3-H); 13C NMR (100 MHz, CDCl3): δ 
208.0 (CO, C-5), 201.9 (CHO, C-1), 42.9 (CH2, C-4), 42.2 (CH2, C-2), 29.9 (CH3, C-6), 15.9 
(CH2, C-3); Calculated C6H11O2+ [M+H]+: 115.0754, found: 115.0758. In accordance 
with literature data. 
5-oxoheptanal[74] 
Pale yellow oil (850 mg, 40% yield). 1H NMR (400 MHz, CDCl3): δ 9.76-
9.75 (1H, m, 1-H), 2.51-2.44 (4H, m, 2,4-H), 2.41 (2H, q, J = 7.3 Hz, 6-H), 
1.90 (2H, m, 3-H), 1.04 (3H, t, J = 7.3 Hz, 7-H). 
(3E)-non-3-ene-2,8-dione (3a)[75] 
Colourless oil (367 mg, 79% yield). R.f. 0.25 (EtOAc/hexane 1:1); FTIR (neat) 
Vmax: 3004 2938, 1712, 1670, 1626, 1358 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 6.75 (1H, dt, J = 16.0, 6.9 Hz, 4-H), 6.06 (1H, d, J = 16.0 Hz, 3-H), 2.50-2.43 
(2H, m, 7-H), 2.28-2.18 (5H, m, 1,5-H), 2.13 (3H, s, 9-H), 1.81-1.70 (2H, m, 6-H); 13C 
NMR (100 MHz, CDCl3): δ 208.1 (CO, C-8), 198.5 (CO, C-2), 147.2 (CH, C-4), 131.7 (CH, 
C-3), 42.6 (CH2, C-7), 31.6 (CH2, C-5), 30.0 (CH3, C-9), 26.9 (CH3, C-1), 21.8 (CH2, C-6); 
LC-MS (m/z): Calculated C9H14O2Na+ [M+Na]+: 177.0886, found: 177.0870. In 
accordance with literature data. 
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(6E)-9,9-dimethyldec-6-ene-2,8-dione (3b)[75] 
The synthesis of 3b was carried out according the general procedure for 
Wittig reactions, but in this case, the reaction mixture was heated to 
reflux for 24 h. Colourless oil (537 mg, 58% yield). R.f. 0.48 
(EtOAc/hexane 1:1); FTIR (neat) Vmax: 2967, 1714, 1687, 1622, 1365, 1077, 983 cm-1; 
1H NMR (400 MHz, CDCl3): δ 6.94-6.82 (1H, m, 6-H), 6.50 (1H, d, J = 15.1 Hz, 7-H), 2.46 
(2H, t, J = 7.3 Hz, 3-H), 2.25-2.20 (2H, m, 5-H), 2.14 (3H, s, 1-H), 1.80-1.70 (2H, m, 4-
H), 1.14 (9H, s, 10-H); 13C NMR (100 MHz, CDCl3): δ 208.3 (CO, C-8), 204.2 (CO, C-2), 
146.2 (CH, C-6), 124.7 (CH, C-7), 42.8 (C, C-9), 42.6 (CH2, C-3), 31.5 (CH2, C-5), 30.0 
(CH3, C-1), 26.1 (CH3, C-10), 22.0 (CH2, C-4); LC-MS (m/z): Calculated C12H21O2+ 
[M+H]+: 197.1536, found: 197.1544. In accordance with literature data. 
(6E)-dodeca-6,11-diene-2,8-dione (3c) 
Pale yellow oil (308 mg, 57% yield). R.f. 0.45 (EtOAc/hexane 1:1); FTIR 
(neat) Vmax: 3078, 2935, 1713, 1668, 1628, 1360, 980, 912 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 6.78 (1H, dt, J = 16.0, 6.9 Hz, 6-H), 6.20-5.99 (1H, m, 
7-H), 5.94-5.62 (1H, m, 11-H), 5.06-4.94 (2H, m, 12-H), 2.63 (2H, t, J = 7.3 Hz, 9-H), 
2.45 (2H, t, J = 7.3 Hz, 3-H), 2.38-2.31 (2H, m, 10-H), 2.25-2.18 (2H, m, 5-H), 2.13 (3H, 
s, 1-H), 1.79-1.68 (2H, m, 4-H); 13C NMR (100 MHz, CDCl3): δ 208.1 (CO, C-2), 199.5 
(CO, C-8), 146.2 (CH, C-6), 137.2 (CH, C-11), 130.7 (CH, C-7), 115.1 (CH2, C-12), 42.5 
(CH2, C-3), 39.1 (CH2, C-9), 31.6 (CH2, C-5), 30.0 (CH3, C-1), 28.0 (CH2, C-10), 21.8 (CH2, 
C-4); LC-MS (m/z): Calculated C12H19O2+ [M+H]+: 195.1380, found: 195.1382. 
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(2E)-1-phenyloct-2-ene-1,7-dione (3d)[75] 
White solid (328 mg, 76% yield). R.f. 0.42 (EtOAc/hexane 1:1); M.p. 
68 – 71 °C; FTIR (neat) Vmax: 3055, 3000, 2955, 2934, 1709, 1663, 
1616, 1356, 1244, 982, 699 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.96-
7.90 (2H, m, 2’-H), 7.60-7.53 (1H, m, 4’-H), 7.51-7.44 (2H, m, 3’-H), 7.03 (1H, dt, J = 
15.5, 6.8 Hz, 3-H), 6.90 (1H, d, J = 15.5, Hz, 2-H), 2.51 (2H, t, J = 7.3 Hz, 6-H), 2.37-2.31 
(2H, m, 4-H), 2.15 (3H, s, 8-H), 1.87-1.78 (2H, m, 5-H); 13C NMR (100 MHz, CDCl3): δ 
208.2 (CO, C-7), 190.7 (CO, C-1), 148.6 (CH, C-3), 137.8 (C, C-1’), 132.7 (CH C-4’), 128.5 
(2CH, C-2’,3’), 126.4 (CH, C-2), 42.6 (CH2, C-6), 31.9 (CH2, C-4), 30.0 (CH3, C-8), 22.0 
(CH2, C-5); LC-MS (m/z): Calculated C14H17O2+ [M+H]+: 217.1223, found: 217.1221. In 
accordance with literature data. 
ethyl (2E)-7-oxooct-2-enoate (3e)[73] 
Colourless oil (171 mg, 66% yield). R.f. 0.41 (EtOAc/hexane 1:1); FTIR 
(neat) Vmax: 2939, 1709, 1653, 1266, 1178, 1148 cm-1; 1H NMR (400 
MHz, CDCl3): δ 6.96-6.85 (1H, dt, J = 15.6, 7.0 Hz, 3-H), 5.82 (1H. d, J 
= 15.6 Hz, 2-H), 4.18 (2H, q, J = 7.2 Hz, 1’-H), 2.45 (2H, t, J = 7.3 Hz, 6-H), 2.23-2.17 
(2H, m, 4-H), 2.13 (3H, s, 8-H), 1.79-1.69 (2H, m, 5-H), 1.28 (3H, t, J = 7.2 Hz, 2’-H); 13C 
NMR (100 MHz, CDCl3): δ 208.2 (CO, C-7), 166.5 (CO, C-1), 148.0 (CH, C-3), 122.0 (CH, 
C-2), 60.2 (CH2, C-1’), 42.6 (CH2, C-6), 31.3 (CH2, C-4), 30.0 (CH3, C-8), 21.8 (CH2, C-5), 
14.2 (CH3, C-2’); LC-MS (m/z): Calculated C10H17O3+ [M+H]+: 185.1172, found: 
185.1147. In accordance with literature data. 
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(3E)-dec-3-ene-2,8-dione (3f) 
The synthesis of 3f was carried out according the general procedure for 
Wittig reactions, but in this case, the reaction mixture was heated to 
reflux for 24 h in THF. Pale yellow oil (770 mg, 69% yield). R.f. 0.37 
(EtOAc/hexane 1:1); FTIR (neat) Vmax: 2976, 2938, 1711, 1698, 1672, 1626, 1458, 
1415, 1360, 1253, 976 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.75 (1H, dt, J = 16.0, 6.9 
Hz, 4-H), 6.06 (1H, d, J = 16.0 Hz, 3-H), 2.48-2.36 (4H, m, 7,9-H), 2.28-2.18 (2H, m, 5-
H), 2.23 (3H, s, 1-H), 1.82-1.71 (2H, m, 6-H), 1.04 (3H, t, J = 7.3 Hz, 10-H); 13C NMR 
(100 MHz, CDCl3): δ 210.8 (CO, C-8), 198.6 (CO, C-2), 147.3 (CH, C-4), 131.7 (CH, C-3), 
41.2 (CH2, C-7), 36.0 (CH2, C-9), 31.7 (CH2¸C-5), 26.9 (CH3, C-1), 21.9 (CH2, C-6), 7.8 
(CH3, C-10); LC-MS (m/z): Calculated C10H17O2+ [M+H]+: 169.1223, found: 169.1220. 
Biotransformations 
General procedure for the preparation of compounds 1a-e 
Commercially available (S)-selective ATA113 or (R)-selective ATA117 (25 mg) was 
rehydrated in HEPES buffer (4.5 mL, 100 mM, pH 7.5) containing PLP (2.00 mM) and 
isopropylamine (0.5 mmol, 2 eq). The pH of the mixture was adjusted to 7.5, using aq 
HCl solution (1 M), and the total volume of the reaction was adjusted to 5 mL by 
addition of HEPES buffer. The ketoenone substrate 3a-e was added (50 mM, 0.5 mL 
from a 500 mM stock solution in DMSO) and the reaction mixture incubated at 30 oC, 
150 rpm for 24-48 h. The reaction was monitored by GC. After completion, the pH of 
the supernatant was adjusted to 12 using aq NaOH solution (4 M) and the resulting 
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mixture was extracted with Et2O (3  10 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure and analysed 
by GC. The crude mixture was dissolved in an alcoholic solvent (5 mL) and stirred at 
the stated temperature for 24-48 h. The crude material was purified by column 
chromatography on silica gel (gradient from CH2Cl2 to 15% MeOH:CH2Cl2) to provide 
pure compounds 1a-e. 
General procedure for the preparation of compound 1f 
Commercially available (S)-selective ATA256 or (R)-selective ATA025 (25 mg) was 
rehydrated in HEPES buffer (4.5 mL, 100 mM, pH 7.5) containing PLP (2.00 mM) and 
isopropylamine (4 eq, 86 uL, 200 mM). The pH of the mixture was adjusted to 7.5, 
using aq HCl solution (1 M), and the total volume of the reaction was adjusted to 4.5 
mL by addition of HEPES buffer. The ketoenone substrate 3f was added (50 mM, 0.5 
mL from a 500 mM stock solution in DMSO) and the reaction mixture incubated at 
50 oC, 150 rpm for 48 h. The reaction was monitored by GC-MS. After completion, 
the pH of the supernatant was adjusted to 12 using aq NaOH solution (4 M) and the 
resulting mixture was extracted with EtOAc (4  20 mL). The combined organic 
extracts were dried over Na2SO4, filtered and concentrated under reduced pressure 
and analysed by GC. The crude mixture was dissolved in an alcoholic solvent (5 mL) 
and stirred at the stated temperature for 24-48 h. The crude material was purified by 
column chromatography on silica gel (gradient from CH2Cl2 to 15% MeOH:CH2Cl2) to 
provide pure compound 1f. 
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(S,S)-(1-[6-methylpiperidin-2-yl]propan-2-one); (S,S)-(+)-pinidinone (1a)[9] 
Yellow oil (36 mg, 93% yield, 99% ee). FTIR (neat) Vmax: 2927, 2859, 1706, 
1360, 1159, 734, 552 cm-1; 1H NMR (400 MHz, CDCl3): δ 3.06-2.96 (m, 
1H), 2.74-2.63 (m, 1H), 2.54 (d, J = 6.4 Hz, 2H), 2.13 (s, 3H), 2.00 (br, s, 
1H), 1.75 (m, 1H), 1.64-1.55 (m, 1H), 1.55-1.47 (m, 1H), 1.43-1.21 (m, 2H), 1.15-0.97 
(m, 2H), 1.04 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 208.5, 52.3, 52.0, 50.6, 
33.8, 31.8, 30.6, 24.6, 23.0; LC-MS (m/z): Calculated C9H18NO+ [M+H]+: 156.1383, 
found: 156.1385. []D24 = +26 (c 3.9, MeOH) {Lit.[]D24 = +25 (c 0.4, MeOH)}. Ee 
determination by chiral GC analysis, CP-Chirasil-DEX CB column, T = 105 °C, P = 6 psi, 
retention times: tr(S,S) = 26.2 min (only enantiomer), tr(R,R) = 24.1 min (not 
observed). In accordance with literature data. 
(R,R)- 1-[6-methylpiperidin-2-yl]propan-2-one); (R,R)-(-)-pinidinone (1a)[10] 
Yellow oil (35 mg, 91% yield, 99% ee). []D24 = 25 (c 2.4, MeOH) {Lit.[ 
]D24 = 4 (c 3.5, MeOH)}. Ee determination by chiral GC analysis, CP-
Chirasil-DEX CB column, T = 105 °C, P = 6 psi, retention times: tr(S,S) = 
26.2 min (not observed), tr(R,R) = 24.1 min (only enantiomer). In accordance with 
literature data. 
3,3-dimethyl-1-[(2S,6S)-6-methylpiperidin-2-yl]butan-2-one (1b) 
Yellow oil (38 mg, 78% yield, 99% ee). FTIR (neat) Vmax: 2962, 2972, 
1700, 1466, 1366, 1062, 732, 570 cm-1; 1H NMR (400 MHz, CDCl3) δ 
3.01-2.90 (m, 1H), 2.73-2.62 (m, 1H), 2.61-2.48 (m, 2H), 1.77-1.66 (m, 
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1H), 1.60-1.44 (m, 2H), 1.43-1.28 (m, 1H), 1.18-0.98 (m, 2H), 1.09 (s, 9H), 1.03 (d, J = 
6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 215.9, 52.6, 52.2, 44.1, 43.4, 33.6, 31.6, 
26.3, 24.5, 22.8; LC-MS (m/z): Calculated C12H24NO+ [M+H]+: 198.1852, found: 
198.1850. []D24 = +15 (c 2.6, MeOH). Ee determination by chiral GC analysis, CP-
Chirasil-DEX CB column, T = 110 °C, P = 6 psi, retention times: tr(S,S) = 47.4 min (only 
enantiomer), tr(R,R) = 44.8 min (not observed). 
3,3-dimethyl-1-[(2R,6R)-6-methylpiperidin-2-yl]butan-2-one (1b) 
Yellow oil (43 mg, 88% yield, 99% ee). []D24 = 16 (c 3.8, MeOH). Ee 
determination by chiral GC analysis, CP-Chirasil-DEX CB column, T = 
110 °C, P = 6 psi, retention times: tr(S,S) = 47.4 min (not observed), 
tr(R,R) = 44.8 min (only enantiomer). 
1-[(2S,6S)-6-methylpiperidin-2-yl]hex-5-en-2-one (1c) 
Yellow oil (45 mg, 92% yield, 99% ee). FTIR (neat) Vmax: 2925, 1709, 
1440, 1373, 1318, 1128, 995, 911, 747, 535 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 5.83-5.67 (m, 1H), 5.05-4.87 (m, 2H), 3.04-2.89 (m, 1H), 2.69-
2.59 (m, 1H), 2.51-2.40 (m, 4H), 2.31-2.19 (m, 3H), 1.76-1.66 (m, 1H), 1.60-1.42 (m, 
2H), 1.41-1.25 (m, 1H), 1.12-0.92 (m, 2H), 1.00 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 209.8, 136.9, 115.2, 52.3, 52.0, 49.6, 42.3, 33.7, 31.8, 27.5, 24.5, 22.9; LC-
MS (m/z): Calculated C12H22NO+ [M+H]+: 196.1696, found: 196.1689. []D24 = 28 (c 
2.1, MeOH). Ee determination by chiral GC analysis, CP-Chirasil-DEX CB column, T = 
125 °C, P = 6 psi, retention times: tr(S,S) = 43.2 min (only enantiomer), tr(R,R) = 40.6 
min (not observed). 
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1-[(2R,6R)-6-methylpiperidin-2-yl]hex-5-en-2-one (1c) 
The synthesis of (R,R)-1c was carried out according to the general 
procedure for biotransformations using ATA117 and 4 equivalent of 
isopropylamine. Yellow oil (44 mg, 90% yield, 99% ee). []D24 = 27 (c 
4.4, MeOH). Ee determination by chiral GC analysis, CP-Chirasil-DEX CB column, T = 
125 °C, P = 6 psi, retention times: tr(S,S) = 43.2 min (not observed), tr(R,R) = 40.6 min 
(only enantiomer). 
2-[(2S,6S)-6-methylpiperidin-2-yl]-1-phenylethanone (1d) 
Yellow oil (41 mg, 76% yield, 99% ee). FTIR (neat) Vmax: 2926, 1680, 
1448, 1223, 751, 731, 689, 572 cm-1; 1H NMR (400 MHz, CDCl3): δ 
7.97-7.89 (m, 2H), 7.59-7.51 (m, 1H), 7.48-7.40 (m, 2H), 3.26-3.15 
(m, 1H), 3.11-3.03 (m, 2H), 2.82-2.69 (m, 1H), 2.55 (br s, 1H), 1.83-1.72 (m, 1H), 1.68-
1.55 (m, 2H), 1.49-1.34 (m, 1H), 1.30-1.17 (m, 1H), 1.17-1.02 (m, 1H), 1.07 (d, J = 6.4 
Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 199.5, 136.9, 133.2, 128.6, 128.0, 52.8, 52.2, 
45.4, 33.8, 32.0, 24.6, 22.9; LC-MS (m/z): Calculated C14H20NO+ [M+H]+: 218.1539, 
found: 218.1543. []D24 = +20 (c 3.0, MeOH). Ee determination by chiral HPLC 
analysis, Lux Amylose-1 column, flow = 0.5 mL/min, hexane/2-propanol 9:1, 
retention times: tr(S,S) = 11.8 min (only enantiomer), tr(R,R) = 27.0 min (not 
observed). 
 
 
55 
 
 
2-[(2R,6R)-6-methylpiperidin-2-yl]-1-phenylethanone (1d) 
The synthesis of (R,R)-1d was carried out according the general 
procedure for biotransformations using ATA117 enzyme and 4 
equivalents of isopropylamine. Yellow oil (24 mg, 44% yield, 99% 
ee). []D24 = 21 (c 1.0, MeOH). Ee determination by chiral HPLC analysis, lux amylose-
1 column, flow = 0.5 mL/min, 90% hexane: 10% 2-propanol, retention times: tr(S,S) = 
11.8 min (not observed), tr(R,R) = 27.0 min (only enantiomer). 
ethyl [(2S,6S)-6-methylpiperidin-2-yl]acetate (1e) 
Yellow oil (33 mg, 72% yield, 99% ee). FTIR (neat) Vmax: 2927, 1729, 
1288, 1188, 115, 1096, 1027, 773, 557 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 4.12 (q, J = 7.1 Hz, 2H), 3.01-2.90 (m, 1H), 2.74-2.61 (m, 
1H), 2.44-2.32 (m, 2H), 2.06 (br s, 1H), 1.80-1.70 (m, 1H), 1.63-1.53 (m, 2H), 1.44-1.29 
(m, 1H), 1.24 (t, J = 7.1 Hz, 3H), 1.16-0.96 (m, 2H), 1.05 (d, J = 6.4 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ 172.5, 60.3, 53.4, 52.2, 41.5, 33.8, 31.9, 24.5, 22.9, 14.2; LC-MS 
(m/z): Calculated C10H20NO2+ [M+H]+: 186.1489, found: 186.1502. []D24 = +21 (c 3.8, 
MeOH). Ee determination by chiral GC analysis, CP-Chirasil-DEX CB column, T = 110 
°C, P = 6 psi, retention times: tr(S,S) = 34.0 min (only enantiomer), tr(R,R) = 32.0 min 
(not observed). 
ethyl [(2R,6R)-6-methylpiperidin-2-yl]acetate (1e) 
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Yellow oil (32 mg, 70% yield, 99% ee). []D24 = 20 (c 3.0, MeOH). 
Ee determination by chiral GC analysis, CP-Chirasil-DEX CB column, 
T = 110 °C, P = 6 psi, retention times: tr(S,S) = 34.0 min (not 
observed), tr(R,R) = 32.0 min (only enantiomer). 
(S,S)-(1-[6-ethylpiperidin-2-yl]propan-2-one) (1f) 
Yellow oil (19 mg, 45% yield, 70% ee). FTIR (neat) Vmax: 3326, 2927, 
2855, 1709, 1458, 1359, 1155, 1111, 963 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 3.03-2.88 (m, 1H), 2.57-2.49 (m, 2H), 2.47-2.35 (m, 1H), 2.11 
(s, 3H), 1.79-1.69 (m, 1H), 1.69-1.60 (m, 1H), 1.54-1.45 (m, 1H), 1.41-1.24 (m, 3H), 
1.16-0.90 (m, 2H), 0.87 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 208.5, 58.3, 
52.4, 50.3, 32.1, 31.5, 30.6, 29.9, 24.4, 10.3; LC-MS (m/z): Calculated C10H20NO+ 
[M+H]+: 170.1538, found: 170.1539. []D24 = +18 (c 3.4, MeOH). Ee determination by 
chiral GC analysis, CP-Chirasil-DEX CB column, T = 110 °C, P = 6 psi, retention times: 
tr(S,S) = 29.4 min (85%), tr(R,R) = 27.4 min (15%). 
(R,R)-(1-[6-ethylpiperidin-2-yl]propan-2-one) (1f) 
Yellow oil (1 mg, 2% yield, 99% ee). []D24 = 60 (c 0.3, MeOH). Ee 
determination by chiral GC analysis, CP-Chirasil-DEX CB column, T = 
110 °C, P = 6 psi, retention times: tr(S,S) = 29.4 min (not observed), 
tr(R,R) = 27.4 min (only enantiomer). 
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3. Investigation into TA Triggered Double-IMAMR  
3.1 Introduction 
The quinolizidine and indolizidine alkaloids are members of a series of azabicyclic 
compounds, frequently found in natural products, which have extensively been 
reviewed.[76] They have received great interest from organic synthetic chemists due 
to their diverse and interesting 3D structure and their corresponding biological 
activity (Scheme 31). The array of biological activities includes antitumor activity 
(martine,[77] swainsonine[78]), antiviral properties (castanospermine[79]) and 
neuroactivity (gephyrotoxin[80]), amongst others. 
The Colombian tropical frog Dendrobates histrionicus has been an abundant source 
of alkaloids with intriguing molecular structures and biological activities, such as 
gephyrotoxin (first isolated in 1977 by Daly and co-workers, Scheme 31).[81] 
Gephyrotoxin derivatives are muscarinic antagonists and thought to be non-toxic. 
Thus, their total synthesis has received much interest.[82–86] 
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Scheme 31: Structures of some quinolizidine and indolizidine natural alkaloids 
 
3.2 Aims and objectives 
Herein we explore the scope of the TA triggered IMAMR to include substrates that 
have the potential to undergo a double IMAMR for the synthesis of quinolizidine and 
indolizidine natural products or their core structures. To do this, we synthesised a 
number of compounds, similar to the previously prepared 3a-e, that contain a second 
conjugated double bond (Scheme 32), generating bis-enone systems that resemble 
Nazarov cyclisation precursors.   
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Scheme 32: Retrosynthetic analysis of quinolizidine and indolizidine via double 
IMAMR 
3.3 Substrate synthesis 
Danishefsky et al. have reported the use of acetone-bis-1,3-triphenylphosphonium 
chloride (17) as precursor for the in-situ preparation of the acetone bisphosphorane 
ylid 18 in the synthesis of (+)-isomigrastatin.[87] The acetone-bis-1,3-
triphenylphosphonium chloride (17) can be readily prepared from dichloroacetone 
and two equivalents of triphenylphosphine in CHCl3, under reflux (Scheme 33).[88] 
Unfortunately, the treatment of 17 with t-BuOK, in order to obtain the desired ylid 
18, followed by the addition of ketoaldehydes 5a,b did not provide the desired Wittig 
olefination products 19 (Scheme 33). Further screening of bases (n-BuLi, LiHMDS and 
K2CO3) were also unsuccessful in this olefination reaction. 
We also attempted a different approach towards the synthesis of 19. 
Dichloroacetone in THF, in the presence of a single equivalent of triphenylphosphine 
under reflux conditions provided α-chloroketo ylid 20 in good yield (78%).[89]. 
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Compound 20 was then reacted with the ketoaldehydes 5a,b to provide novel 
ketoenones 21a,b in 39 and 31% yield, respectively. The reaction of the -chloro 
ketoenones 21a,b with PPh3 in THF was unsuccessful at either room temperature or 
under reflux conditions. However, although the targeted phosphorus enone 19 was 
not achieved, compounds 21a,b are themselves, interesting substrates to study in a 
biocatalysed transamination reaction.  
 
Scheme 33: Attempted synthesis of phosphorus enone 19 from dichloroacetone  
Danishefsky’s et al. report on the bisphosphorane 18 highlights the difficulties in the 
purification of the crude reaction when this reagent is employed. Therefore, they 
modified their synthetic route to utilise the corresponding Horner-Wadsworth-
Emmons (HWE) reagent.[87] We also applied this strategy, based on the addition of 
the anion of methyl diethylphosphonate to a suitable ester precursor, and developed 
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both a linear and a convergent route to the bis-conjugated enones 25a (Scheme 34) 
and 25b (Scheme 35).   
The initially employed linear route involved the selective protection of keto-esters 
3e,g, which provided ketals 22a,b in 80 and 70% yield, respectively (Scheme 34). The 
nucleophilic attack of the deprotonated methyl phosphonate to the ester moiety of 
compounds 22a,b only proceeded for the methyl ester substrate (R = Me, 22a), 
providing 23a in 74% yield. The deprotonation of 23a with K2CO3 in THF followed by 
reaction with acetaldehyde provided 24a in 28% yield, which upon deprotection with 
catalytic p-TsOH in a mixture of acetone:H2O (3:1), provided our target ketodienone 
25a in 20% yield.  
Scheme 34: Direct synthetic route utilising a HWE to dienone-ketone 25a 
The convergent synthetic route towards 25b involved the use of the corresponding 
HWE reagent 28 (Scheme 35). The reaction of ethyl crotonate with deprotonated 
diethyl methylphosphonate provided diethyl [(3E)-2-oxopent-3-en-1-yl]phosphonate 
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(28) in 51% yield.[90] The ketal aldehyde 27 was readily prepared by protection of 6-
methyl-5-hepten-2-one with ethylene glycol under acidic conditions, to provide 26, 
followed by oxidative cleavage of the double bond (following the same method used 
for the preparation of compound 5a) providing compound 27 in 36% yield.[91] 
Subsequent Wittig reaction of 27 and 28 provided compound 24b in 32% yield. Later, 
deprotection under the previously optimised reaction conditions, resulted in the 
formation of ketodienone 25b in 21% yield.   
 
Scheme 35: Convergent synthetic route to dienone-ketone 25b 
A novel 1-cyclohex-1-enyl-2-(triphenylphosphanylidene)ethanone (30) ylid reagent 
has also been prepared, as a useful reagent towards the synthesis of two substrates 
containing bis-conjugated enones (Scheme 36). Iwasawa et al. report the -
bromination of 1-cyclohexenylmethylketone via enolate trapping with TMSCl and 
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subsequent reaction with NBS, to provide 29 in 62% yield.[92] The reaction of 
bromoketone 29 with triphenylphosphine, in THF under reflux conditions, generated 
the corresponding phosphonium salt, which was subsequently deprotonated with 
NaOH in methanol to provide the stable novel phosphorus ylid 30. Reaction of 30 
with ketoaldehydes 5a,b in CHCl3 at r.t., provided compounds 30a,b in 81 and 36% 
yield, respectively, after purification by flash chromatography.   
 
Scheme 36: Novel 1-cyclohex-1-enyl-2-(triphenylphosphanylidene)ethanone reagent 
for the synthesis of bis-conjugated enones 30a,b 
3.4 Transamination of substrates 21a,b, 25a,b and 30a,b 
The transamination reaction of compounds 21a,b and 25a,b was evaluated in the 
presence of four different Codexis enzymes (Table 6). Using the previously optimised 
reaction conditions (see section 2.4 of this thesis), at the optimal working 
temperature for each enzyme (see Table 6), no conversion into the desired amine 
product was observed (Table 6, entries 1-4). Instead, complete decomposition of the 
starting material took place after a reaction time of 24 h. An excess of IPA was also 
employed in the reaction with ATA117 at 30 oC (Table 6, entry 5), but no effect on 
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the outcome of the reaction was observed. The reaction with ATA 256 at 50 oC was 
attempted at pH 7.0 and 9.0 (Table 6, entry 6 and 7), but no conversion into the 
desired amine product was observed in any case. The control experiment where no 
enzyme was present also resulted in the complete decomposition of starting 
materials (Table 6, entry 8).  
Table 6: Screening of transamination conditions for compounds 21a,b and 25a,ba,b,c 
 
Entry ω-TA Temp (°C) pH IPA (eq) Conv. (%) 
1 ATA113 30 7.5 2 decomp 
2 ATA117 30 7.5 2 decomp 
3 ATA256 50 7.5 2 decomp 
4 ATA025 50 7.5 2 decomp 
5 ATA117 30 7.5 20 decomp 
6 ATA256 50 7.0 2 decomp 
7 ATA256 50 9.0 2 decomp 
8 - 30 7.5 2 decomp 
a Reaction conditions: (i) ω-TA (5 mg/mL), substrate (50 mM), PLP 
(2 mM), HEPES buffer (1 mL, 100 mM), 150 rpm, 24 h. b Complete 
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decomposition of the starting material was observed for all 
entries. c Reactions monitored by GC-MS.  
 
Regarding the biocatalysed transamination reaction of compounds 30a,b, our initial 
screening, with ATA113 and ATA117 Codexis enzymes, showed that, under the 
previously optimised conditions at 30 °C (see chapter 2.4), no reaction took place 
(Table 7, entry 1,2) and all the starting material could be recovered at the end of the 
reaction. However, the use of ATA025 and ATA256 at higher temperature (50 °C), 
provided full conversion of the starting material (Table 7, entry 3,4).  
Table 7: Screening of transamination conditions for compounds 30a,ba,b 
 
Entry ω-TA Temp (°C) Conv. of 30a and 30b (%) 
1 ATA113 30 0 
2 ATA117 30 0 
3 ATA256 50 >99% 
4 ATA025 50 >99% 
a Reaction conditions: (i) ω-TA (5 mg/mL), substrate (50 mM), PLP 
(2 mM), HEPES buffer (5 mL, 100 mM, pH 7.5), isopropylamine 
(100 mM), 150 rpm, 24 h. b Reactions monitored by GC-MS. 
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The transamination reaction of 30a provided five compounds, with the major 
product, arising from single IMAMR being isolated as compound 31a in 45% yield and 
31b, the double IMAMR product as an inseparable mixture of stereoisomers (Scheme 
37). Dissolving compound 31b and/or 31a in MeOH (at r.t or reflux) resulted in no 
epimerisation in any capacity. Previous work on tetrasubstituted quinolizidines,[93] 
similar to compound 31a, by Pill et al., describes that heating in MeOH and aq. NH3 
in a sealed vessel, catalyses an IMAMR in this kind of system. Our attempts to induce 
the second IMAMR in 31a in MeOH and aq NH3 and heating in a microwave reactor 
resulted in product degradation. We also explored the possibility of epimerising the 
mixture of 31a,b isomers under these conditions, which again, resulted in 
degradation of the products (Scheme 38).  
 
Scheme 37: Transamination of compound 30a 
In comparison, the biocatalysed transamination of compound 30b with ATA256 at 50 
oC, produced three stereoisomers all rising from double aza-Michael addition, with 
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compound 32a being the major product (approx. 62% calculated yield based on 1H-
NMR analysis, by integration of 1-H and 3a-H, Scheme 38). However, upon flash 
column chromatography on silica gel, compound 32a epimerised to a 1:1:1 mixture 
of compounds 32a-c. Purification by flash chromatography allowed the isolation of 
compounds 32a and 32b in 26 and 20% yield, respectively (Scheme 38). 
 
Scheme 38: Transamination of compound 30b into three stereoisomers 32a-c 
The relative stereochemistry of compound 32a was confirmed by 2D-NMR 
experiments. In the NOESY spectrum (Figure 3A), we observe a coupling between the 
Me group and HB (J1) indicating a trans-configuration in the pyrrolidine ring. For Hc, 
we see a coupling with the Me group and Hb (J2 and 3), however, it does not couple 
to Hd. Therefore, we can assign the absolute configuration of 32a as S,R,S,S (Figure 
3A). 
The relative stereochemistry of compound 32b was also confirmed by 2D-NMR 
experiments. The corresponding NOESY spectrum, showed a coupling between the 
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Me group and HB (J1), indicating a trans-configuration in the pyrrolidine ring. For Hc 
we see a coupling with the Me group (J2), however, this time we do not see a coupling 
to Hb. Finally, between Hc and Hd we see a coupling showing a cis-fused cyclohexane/ 
piperidin-4-one configuration, leading to the assignment of the absolute 
configuration of 32b as S,R,R,S (Figure 3B). 
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Figure 3: A) NOESY analysis of isomers 32a B) NOESY analysis of isomers 32b 
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3.5 Conclusion and future work 
In conclusion, two novel α-chloroenones 21a,b have been synthesised. However, 
attempted transamination of these substrates resulted in complete decomposition 
of starting materials. We have also developed both direct and convergent 
methodologies for the synthesis of diconjugated substrates 25a,b, resembling 
Nazarov precursors, utilising a HWE intermediate. Subsequent exposure of these 
diconjugated substrates, to the previously optimised TA-IMAMR conditions, resulted 
in complete decomposition of the starting materials in the reaction media.  
A novel phosphorus yild 30 was synthesised and employed to provide diconjugated 
enones 30a,b. These proved to be interesting substrates for a biocatalytic 
transamination, undergoing complete conversion under newly optimised conditions 
with ATA256, providing assorted products. Compound 30a preferentially underwent 
a mono-IMAMR providing compound cis-31a as the major product. An unsuccessful 
attempt was made to epimerise and/or catalyse the second potential IMAMR. 
Therefore, compound 31a has been here reported as the only isolated compound. 
Compound 30b exclusively underwent a double IMAMR cascade providing 
compound 32a as the major isomer (approx. 62% calculated yield based on 1H-NMR) 
and a mixture of 32b,c. Epimerisation attempts of 32a-c resulted in a 1:1:1 mixture 
of isomers. Silica gel column chromatography resulted in the epimerisation of 32a-c 
and therefore 32a was isolated in a 26% yield and 32b in a 20% yield. The absolute 
configurations of 32a,b were determined by NOESY experiments. 
Other methods of catalysing the IMAMR of 31a should be examined. If successful, a 
secondary precaution could include the selective reduction of the carbonyl group to 
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prevent epimerisation and/or a retro Michael reaction occurring. Any future attempt 
at the isolation of the compound 32a-c should also include the selective reduction of 
the carbonyl group to prevent epimerisation, and therefore, increasing the isolated 
yield of the reduced 32a, which would contain five stereogenic centres in good yield 
from a prochiral substrate. Finally, other α,β-substituted enones (similar to 30a,b) 
could be investigated as substrates for transamination to see if the scope of the 
double-IMAMR can be expanded.  
3.6 Experimental 
For general methods and materials, see experimental section 2.6.  
2-methyl-2-(4-methylpent-3-en-1-yl)-1,3-dioxolane (26)[94] 
To 6-methyl-5-hepten-2-one (2.95 mL, 20 mmol) in toluene (20 
mL), ethylene glycol (4.46 mL, 80 mmol) and p-TsOH (76 mg, 4.0 
mmol) were added and the mixture was refluxed for a period of 6 h in a Dean-Stark 
apparatus, to remove water from the reaction mixture. The reaction mixture was 
then concentrated to remove the toluene and the resulting residue was diluted with 
Et2O (100 mL) and washed successively with sat. NaHCO3 solution, water and brine 
(2  50 mL each). The organic layer was then dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel to provide the title compound as a colourless oil (2.25 
g, 66% yield). R.f. 0.31 (Et2O/Hexane 1:9); 1H NMR (400 MHz, CDCl3) δ 5.10 (1H, s, 3’-
H), 3.99-3.87 (4H, m, 1,3-H), 2.14-1.99 (2H, m, 2’-H), 1.73-1.58 (8H, m, 1’,5’,1’’’-H), 
1.32 (3H, s, 1’’-H); 13C NMR (100 MHz, CDCl3): δ 131.6 (C, C-4’), 124.0 (CH, C-3’), 109.9 
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(C, C-2), 64.6 (CH2, C-1,3), 39.1 (CH2, C-1’), 25.7 (CH3), 23.8 (CH3), 22.7 (CH2, C-2’), 17.6 
(CH3). 
General Procedure for the oxidative cleavage of 6-methyl-5-hepten-2-one and 2-
methyl-2-(4-methylpent-3-en-1-yl)-1,3-dioxolane 
The corresponding 6-methyl-5-hepten-2-one or 2-methyl-2-(4-methylpent-3-en-1-
yl)-1,3-dioxolane (26) (1 eq, 16.6 mmol) and OsO4 (4% w.t/v tBuOH, 0.01 eq, 0.17 
mmol, 1.06 mL) were added to a solution of N-methylmorpholine N-oxide (2 eq, 33.2 
mmol, 3.89 g) in acetone (20 mL). The mixture was stirred at room temperature for 
4 h and then quenched with sat. aq. Na2SO3 solution (80 mL) and extracted with 
CH2Cl2 (3  60 mL). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude material was dissolved in water 
(20 mL) and sodium periodate (2 eq, 33.2 mmol, 7.10 g) was added. The resulting 
mixture was stirred for 1 h at room temperature and then diluted with water (60 mL) 
and extracted with CH2Cl2 (3 x 30 mL). Next, the combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure to provide 5b 
and 27, which were used in the next step without further purification. 
4-oxopentanal (5b)[95] 
Colourless oil (3.85 g, 77 % yield). 1H NMR (400 MHz, CDCl3) δ 9.78 
(1H, s, 1-H), 2.74 (4H, s, 2,3-H), 2.19 (3H, s, 5-H); 13C NMR (100 MHz, 
CDCl3): δ 206.4 (CO, C-4), 200.1 (CHO, C-1), 37.4 (CH2, C-2), 35.4 (CH2, C-3), 29.7 (CH3, 
C-5). 
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3-(2-methyl-1,3-dioxolan-2-yl)propanal (27)[96]  
Pale yellow oil (1.03 g, 36% yield). 1H NMR (400 MHz, CDCl3) δ 9.71 
(1H, s, 3’-H), 3.98-3.83 (4H, m, 1,3-H), 2.51-2.42 (2H, m, 2’-H), 2.06 
(2H, t, J = 7.1 Hz, 1’-H), 1.33 (3H, s, 1’’-H); 13C NMR (100 MHz, CDCl3): δ 202.1 (CO, C-
3’), 109.1 (C, C-2), 64.7 (CH2, C-1,3), 38.4 (CH2, C-2’), 31.8 (CH2, C-1’), 24.1 (CH3, C-1’’). 
2-oxotrimethylene-1,3-bis(triphenylphosphonium) chloride (17)[88] 
To 1,3-dichloroacetone (1.0 eq, 23.6 mmol, 3.00 g) in CHCl3 (100 
mL) was added triphenylphosphine (2.2 eq, 47.2 mmol, 13.64 g) 
and the mixture stirred under reflux for 24 h. The resulting solid was collected by 
filtration and washed with Et2O to provide the title compound as a white solid (11.07 
g, 72% yield). 1H NMR (400 MHz, CDCl3) δ 7.86 (12H, m), 7.66 (6H, m), 7.54 (m, 12H), 
6.89 (4H, d, J = 11.0 Hz, 1,3-H). 
1-chloro-3-(triphenylphosphoranylidene)acetone (20)[89] 
To 1,3-dichloroacetone (1.0 eq, 23.6 mmol, 3.00 g) in THF (100 mL) 
was added triphenylphosphine (1.1 eq, 26.0 mmol, 6.82 g) and the 
mixture stirred under reflux for 4 h. The resulting solid was collected by filtration, 
washed with Et2O and then redissolved in the minimal volume of MeOH/H2O (1:1). 
NaOH (2 M) was added until pH 8 was reached and the mixture was allowed to stir 
at room temperature for 24 h. The MeOH was then removed by vacuum filtration 
and then the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The organic layers 
were combined and dried over MgSO4, filtered and concentrated under reduced 
pressure to provide the title compound as a pale orange solid. (6.52 g, 78% yield). 1H 
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NMR (400 MHz, CDCl3) δ 7.69-7.61 (6H, m), 7.60-7.52 (3H, m, 4’-H), 7.51-7.44 (6H, 
m), 4.28 (1H, d, J = 23.8 Hz, 3-H), 4.02 (2H, s, 1-H); 
(3E)-1-chloronon-3-ene-2,8-dione (21a) 
To 1-chloro-3-(triphenylphosphoranylidene)acetone (2.0 eq, 8.42 
mmol, 2.97 g) in CHCl3 (20 mL) was added ketoaldehyde 5a (1.0 eq, 
4.21 mmol, 422 mg) and the mixture stirred under refluxed for 24 h. 
The reaction mixture was concentrated under reduced pressure and purified by 
column chromatography on silica gel to provide the title compound as a yellow oil 
(175 mg, 39% yield). R.f. 0.39 (EtOAc/CHCl3 1:9); FTIR (neat) Vmax: 2928, 1708, 1694, 
1626, 1359, 1160, 901, 774 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.01-6.90 (1H, m, 4-H), 
6.36-6.27 (1H, m, 3-H), 4.20 (2H, s, 1-H), 2.50-2.43 (2H, m, 7-H), 2.31-2.22 (2H, m, 5-
H), 2.14 (3H, s, 9-H), 1.82-1.71 (2H, m, 6-H); 13C NMR (100 MHz, CDCl3): δ 207.9 (CO, 
C-8), 191.0 (CO, C-2), 149.4 (CH, C-4), 126.5 (CH, C-3), 47.0 (CH2, C-1), 42.4 (CH2, C-7), 
31.7 (CH2, C-5), 30.0 (CH3, C-9), 21.6 (CH2, C-6); LC-MS (m/z): Calculated C9H14ClO2+ 
[M+H]+: 189.0677, found: 189.0661. 
(3E)-1-chlorooct-3-ene-2,7-dione (21b) 
To 1-chloro-3-(triphenylphosphoranylidene)acetone (2.0 eq, 8.42 
mmol, 2.97 g) in CHCl3 (20 mL) was added ketoaldehyde 5b (1.0 eq, 
4.21 mmol, 422 mg) and the mixture stirred under reflux for 24 h. The 
reaction mixture was concentrated under reduced pressure and purified by column 
chromatography on silica gel to provide the title compound as a yellow oil (228 mg, 
31% yield). R.f. 0.33 (EtOAc/CHCl3 1:9); FTIR (neat) Vmax: 2927, 1709, 1628, 1404, 
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1359, 1193, 1160, 979, 772 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.00-6.90 (1H, m, 4-H), 
6.35-6.27 (1H, m, 3-H), 4.19 (2H, s, 1-H), 2.66-2.60 (2H, m, 6-H), 2.55-2.47 (2H, m, 5-
H), 2.16 (3H, s, 8-H); 13C NMR (100 MHz, CDCl3): δ 206.5 (CO, C-7), 190.9 (CO, C-2), 
148.4 (CH, C-4), 126.5 (CH, C-3), 47.0 (CH2, C-1), 41.2 (CH2, C-6), 29.9 (CH3, C-8), 26.3 
(CH2, C-5); LC-MS (m/z): Calculated C8H12ClO2+ [M+H]+: 175.0520, found: 175.0515. 
methyl (2E)-7-oxooct-2-enoate (3g)[97] 
Compound 3g was prepared following the same procedure for 
compounds 3a-e. Colourless oil (1.01 g, 68% yield). R.f. 0.42 
(EtOAc/hexane 1:1); 1H NMR (400 MHz, CDCl3): δ 6.91 (1H, dt, J = 15.6, 
6.9 Hz, 3-H), 5.85-5.80 (1H, m, 2-H), 3.72 (3H, s, 1’-H), 2.45 (2H, t, J = 7.1 Hz, 6-H), 
2.24-2.18 (2H, m, 4-H), 2.13 (3H, s, 8-H), 1.78-1.69 (2H, m, 5-H); 13C NMR (100 MHz, 
CDCl3): δ 208.1 (CO, C-7), 166.9 (CO, C-1), 148.3 (CH, C-3), 121.6 (CH, C-2), 51.4 (CH2, 
C-1’), 42.5 (CH2, C-6), 31.3 (CH2, C-4), 30.0 (CH3, C-8), 21.8 (CH2, C-5). 
methyl (2E)-6-(2-methyl-1,3-dioxolan-2-yl)hex-2-enoate (22a) 
To compound 3g (1.0 eq, 5.29 mmol, 0.90 g) in toluene (50 mL) and p-
TsOH (0.10 eq, 0.53 mmol, 101 mg) and ethylene glycol (3.0 eq, 15.87 
mmol, 0.89 mL) were added and the mixture was refluxed for a period 
of 6 h in a Dean-Stark apparatus, to remove water from the reaction mixture. The 
reaction mixture was then concentrated to remove the toluene and the resulting 
residue was diluted with Et2O (100 mL) and washed successively with sat. NaHCO3 
solution, water and brine (2  50 mL each). The organic layer was then dried over 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified 
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by column chromatography on silica gel to provide the title compound as a colourless 
oil (760 mg, 75% yield). R.f. 0.31 (EtOAc/hexane 1:1); FTIR (neat) Vmax: 2984, 2949, 
2876, 1720, 1656, 1436, 1376, 1270, 1197, 1171, 1039, 853 cm-1; 1H NMR (400 MHz, 
CDCl3): δ 6.95 (1H, dt, J = 15.7, 7.1 Hz, 3-H), 5.87-5.76 (1H, m, 2-H), 3.97-3.87 (4H, m, 
1’’-H), 3.72 (3H, s, 1’-H), 2.26-2.17 (2H, m, 4-H), 1.68-1.62 (2H, m, 6-H), 1.60-1.52 (2H, 
m, 5-H), 1.30 (3H, s, 8-H); 13C NMR (100 MHz, CDCl3): δ 167.1 (CO, C-1), 149.2 (CH, C-
3), 121.1 (CH, C-2), 109.8 (CO, C-7), 64.7 (CH2, C-1’’), 51.4 (CH2, C-1’), 38.5 (CH2, C-6), 
32.2 (CH2, C-4), 23.8 (CH3, C-8), 22.4 (CH2, C-5); LC-MS (m/z): Calculated C11H19O4+ 
[M+H]+: 215.1278, found: 215.1272.  
diethyl [(3E)-7-(2-methyl-1,3-dioxolan-2-yl)-2-oxohept-3-en-1-yl]phosphonate 
(23a) 
To methyl diethylphosphonate (1.0 eq, 1.78 mmol, 0.26 mL) in THF 
(10 mL) at –78 °C was added n-BuLi (1.2 eq, 2.13 mmol, 0.79 mL) 
and the mixture stirred for 15 mins. Compound 22b (1.0 eq, 1.78 
mmol, 381 mg) in a solution of THF (2 mL) was then added slowly and the mixture 
allowed to stir for 12 h. The reaction mixture was then quenched with sat. NH4Cl (10 
mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed 
with brine (20 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified by vacuum distillation and then eluted through a 
silica pad with MeOH/DCM (1:9) to provide the title compound as a pale yellow oil 
(384 mg, 74% yield). FTIR (neat) Vmax: 2981, 2939, 1730, 1665, 1625, 1376, 1247, 
1018, 961, 856, 799 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.97-6.86 (m, 1H), 6.27-6.18 
(m, 1H), 4.19-4.00 (m, 4H), 3.99-3.85 (m, 4H), 3.19 (2H, d, J = 22.9 Hz, 1-H), 2.30-2.21 
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(2H, m, 5-H), 1.74-1.53 (4H, m, 6,7-H), 1.37-1.27 (9H, m); LC-MS (m/z): Calculated 
C15H28O6P+ [M+H]+: 335.1618, found: 335.1616.  
(2E,5E)-9-(2-methyl-1,3-dioxolan-2-yl)nona-2,5-dien-4-one (24a) 
To compound 23b (1.0 eq, 3.11 mmol, 904 mg) dissolved in dry THF 
(10 mL) at 0 °C was added K2CO3 (5.0 eq, 15.57 mmol, 2.15 mg) and 
the mixture stirred for 15 mins. Acetaldehyde (10 eq, 31.14 mmol, 
1.74 mL) was then added and the mixture stirred for a further 12 h. The crude 
reaction mixture was filtered, concentrated under reduced pressure and purified by 
column chromatography on silica gel to provide the title compound as a colourless 
oil (195 mg, 28% yield). R.f. 0.40 (EtOAc/hexane 1:1); FTIR (neat) Vmax: 2982, 2941, 
2877, 1717, 1666, 1636, 1614, 1443, 1375, 1295, 1204, 1060, 976, 862 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 7.01-6.78 (2H, m, 2,6-H), 6.43-6.22 (2H, m, 3,5-H), 4.03-3.82 (4H, 
m, 1’,3’-H), 2.29-2.19 (2H, m, 7-H), 1.91 (3H, dd, J = 6.9, 1.4 Hz, 1-H), 1.70-1.62 (2H, 
m, 9-H), 1.62-1.52 (2H, m, 8-H), 1.30 (3H, s, 1’’-H); 13C NMR (100 MHz, CDCl3): δ 189.4 
(CO, C-4), 147.3 (CH, C-6), 143.0 (CH, C-2), 130.2 (CH, C-3), 128.8 (CH, C-5), 109.8 (C, 
C-2’), 64.6 (2CH2, C-1’,3’), 38.6 (CH2, C-9), 32.6 (CH2, C-7), 23.8 (CH3, C-1’’), 22.5 (CH2, 
C-8), 18.4 (CH3, C-1); LC-MS (m/z): Calculated C13H21O3+ [M+H]+: 225.1485, found: 
225.1479. 
(6E,9E)-undeca-6,9-diene-2,8-dione (25a) 
To 24a (1.0 eq, 0.83 mmol, 150 mg) dissolved in acetone:H2O (3:1, 8 
mL) was added p-TsOH (0.05 eq, 0.042 mmol, 8.0 mg) and the mixture 
stirred for 24 h. The reaction mixture was diluted with brine (10 mL) 
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and extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were then 
washed with brine (10 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel 
to provide the title compound as a colourless oil (30 mg, 20% yield). R.f. 0.31 
(EtOAc/hexane 1:1); FTIR (neat) Vmax: 2937, 1711, 1665, 1636, 1612, 1440, 1357, 
1294, 1204, 1161, 979, 746 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.96-6.78 (2H, m, 6,10-
H), 6.38-6.26 (2H, m, 7,9-H), 2.45 (2H, t, J = 7.3 Hz, 3-H), 2.29-2.18 (2H, m, 5-H), 2.12 
(3H, s, 1-H), 1.91 (3H, dd, J = 6.9, 1.8 Hz, 11-H), 1.81-1.68 (2H, m, 4-H); LC-MS (m/z): 
Calculated C10H15O2+ [M+H]+: 181.1223, found: 181.1217 
diethyl [(3E)-2-oxopent-3-en-1-yl]phosphonate (28)[90] 
To diethyl methylphosphonate (1.0 eq, 20 mmol, 2.92 mL) in 
THF (80 mL) at 78 °C was added n-BuLi (1.2 eq, 24 mmol, 2.5 
M, 9.60 mL) and the mixture stirred for 30 min. Ethyl crotonate (1.2 eq, 24 mmol, 
2.98 mL) in THF (10 mL) was then added slowly and the mixture stirred for 24 h at 
78 °C. The reaction mixture was then quenched with sat. NH4Cl and extracted with 
EtOAc (3 x 50 mL). The combined organic layers were washed with brine (100 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure. The residue 
was purified by vacuum distillation to provide the title compound as a yellow oil (2.23 
g, 51% yield). 1H NMR (400 MHz, CDCl3): δ 7.06-6.86 (1H, m, 4-H), 6.34-6.16 (1H, m, 
3-H), 4.26-3.96 (4H, m, 1’-H), 3.19 (2H, d, J = 22.9 Hz, 1-H), 1.97-1.90 (3H, m, 5-H), 
1.36-1.27 (6H, m, 2’-H). 
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(2E,5E)-8-(2-methyl-1,3-dioxolan-2-yl)octa-2,5-dien-4-one (24b) 
To a solution of 28 (2.0 eq, 2.0 mmol, 304 mg) and K2CO3 (5.0 eq, 5.0 
mmol, 691 mg) in dry THF (20 mL) was added 27 (1.0 eq, 1.0 mmol 
144 mg) and the mixture stirred at 0 °C for 24 h. The reaction mixture 
was then filtered, concentrated under reduced pressure and the 
residue was purified by column chromatography on silica gel to provide the title 
compound as a colourless oil (68 mg, 32% yield). FTIR (neat) Vmax:  2936, 1713, 1665, 
1376, 1163, 1042, 973, 861 731 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.98-6.82 (2H, m, 
2,6-H), 6.38-6.27 (2H, m, 3,5-H), 3.99-3.85 (4H, m, 1’,3’-H), 2.38-2.28 (2H, m, 7-H), 
1.91 (3H, dd, J = 6.9, 1.4 Hz, 1’-H), 1.85-1.77 (2H, m, 8-H), 1.33 (3H, s, 1’’-H); 13C NMR 
(100 MHz, CDCl3): δ 189.4 (CO, C-4), 147.4 (CH, C-6), 143.0 (CH, C-2), 130.2 (CH, C-3), 
128.4 (CH, C-5), 109.4 (C, C-2’), 64.7 (2CH2, C-1’,3’), 37.4 (CH2, C-8), 27.2 (CH2, C-7), 
24.0 (CH3, C-1’’), 18.4 (CH3, C-1); LC-MS (m/z): Calculated C12H19O3+ [M+H]+: 
211.1329, found: 211.1326. 
(5E,8E)-deca-5,8-diene-2,7-dione (25b) 
To a solution of 24b (1 eq, 0.32 mmol, 68 mg) in acetone:H2O (3:1, 4 
mL) was added p-TsOH (0.05 eq, 0.016 mmol, 3 mg) and the mixture 
was stirred at r.t. for 12 h. The resulting mixture was diluted with 
brine (5 mL) and extracted with EtOAc (3 x 10 mL). The combined 
organic layers were then washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude material was purified by column 
chromatography on silica gel to provide the title compound as a colourless oil (11 mg, 
21% yield). R.f. 0.28 (EtOAc/hexane 1:1); FTIR (neat) Vmax: 2913, 1712, 1665, 1637, 
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1613, 1441, 1358, 1288, 1161, 977, 868 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.00-6.73 
(2H, m, 5,9-H), 6.40-6.22 (2H, m, 6,8-H), 2.65-2.56 (2H, m, 3-H), 2.52-2.44 (2H, m, 4-
H), 2.15 (3H, s, 1-H), 1.90 (3H, dd, J = 6.9, 1.4 Hz, 10-H); 13C NMR (100 MHz, CDCl3): δ 
206.9 (CO, C-2), 189.1 (CO, C-7), 145.4 (CH, C-5), 143.3 (CH, C-9), 130.2 (CH, C-8), 
129.1 (CH, C-6), 41.6 (CH2, C-3), 29.9 (CH3, C-1), 26.3 (CH2, C-4), 18.4 (CH3, C-10); LC-
MS (m/z): Calculated C10H15O2+ [M+H]+: 167.1067, found: 161.1060 
1-(1-trimethylsilyloxy)vinyl-1-cyclohexene[98] 
To a solution of diisopropylamine (4.23 mL, 30 mmol) in dry THF (20 mL) 
at 78 °C was added n-BuLi (12 mL, 2.5 M, 30 mmol) and the mixture 
was allowed to warm to 40 °C and stirred for 20 mins. The reaction 
was then cooled to 78 °C and 1-acetylcyclohex-1-ene (2.57 mL, 20 mmol) in dry THF 
(5 mL) was added dropwise and was stirred for 1 h. Trimethylsilyl chloride (3.81 mL, 
30 mmol) was then added and the mixture was allowed to warm to r,t, overnight. 
The THF was removed under reduced pressure and the residue diluted with hexanes. 
The mixture was then filtered quickly through a sintered funnel. The residue was 
concentrated under reduced pressure to provide the crude title compound as a 
colourless oil. 1H NMR (400 MHz, CDCl3): δ 6.19 (1H, m, 2’-H), 4.27 (2H, d, J = 64.1 Hz, 
2-H), 2.12 (4H, m, 3’,6’-H), 1.71-1.53 (4H, m, 4’,5’-H), 0.22 (9H, s, 1’’-H); 13C NMR (100 
MHz, CDCl3): δ 156.5 (C, C-1), 133.0 (C, C-1’), 125.4 (CH, C-2’), 89.7 (CH2, C-2), 25.4 
(CH2), 24.9 (CH2), 22.7 (CH2), 22.1 (CH2), 0.0 (CH3, C-1’’). 
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1-bromo-2-(cyclohex-1-enyl)ethan-2-one (29)[99] 
N-bromosuccinimide (3.56 g, 20 mmol) was added to a THF solution 
(30 mL) of the crude silyl enol ether at –40 °C and the mixture was 
stirred overnight at the same temperature. The mixture was then poured into sat. 
aq. Na2S2O3 solution (60 mL) and the aqueous layer extracted with EtOAc (3 x 30 mL). 
The combined organic extracts were then washed with brine (2  60 mL), dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude material was 
purified by column chromatography on silica gel (EtOAc 1:9 Hexane) to provide the 
title compound as an orange oil (2.53 g, 62% yield). R.f 0.31 (EtOAc 1:9 Hexane); 1H 
NMR (400 MHz, CDCl3): δ 6.99 (1H, m, 2’-H), 4.17 (2H, s, 1-H), 2.39-2.18 (4H, m, 3’,6’-
H), 1.74-1.54 (4H, m, 4’,5’-H); 13C NMR (100 MHz, CDCl3): δ 199.2 (C, C-2), 142.9 (CH, 
C-2’), 136.9 (C, C-1’), 30.0 (CH2, C-1), 26.3 (CH2), 23.2 (CH2), 21.7 (CH2), 21.3 (CH2). 
1-cyclohex-1-enyl-2-(triphenylphosphanylidene)ethanone (30) 
To 1-bromo-2-(cyclohex-1-enyl)ethan-2-one (1.0 eq, 10 mmol, 2.04 
g) in THF (20 mL) was added triphenylphosphine (1.0 eq, 10 mmol, 
2.62 g) and heated to reflux for 4 h. The reaction was allowed to cool to r.t. and the 
precipitate was collected by filtration. The solid was then suspended in MeOH:H2O 
(1:1, 50 mL) and NaOH solution (1 M) was added until the mixture became slightly 
basic and stirred for 24 h. The MeOH was removed under reduced pressure and the 
aqueous solution was extracted with CHCl3 (3 x 30 mL). The combined organic 
extracts were then washed with brine (30 mL) and dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude solid was recrystallised in EtO2 to 
provide the title compound as a beige solid (2.96 g, 77% yield). FTIR (neat) Vmax: 2923, 
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1511, 1480, 1433, 1385, 1157, 1103, 889, 714, 690 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 7.70-7.62 (6H, m, 2’’-H), 7.56-7.49 (3H, m, 4’’-H), 7.48-7.41 (6H, m, 3’’-H), 6.68-6.59 
(1H, m, 2’-H), 3.95 (1H, d, J = 26.4 Hz, 2-H), 2.40-2.36 (2H, m), 2.16-2.13 (2H, m), 1.69-
1.63 (2H, m), 1.60-1.54 (2H, m); 13C NMR (100 MHz, CDCl3): δ 187.0 (CO, C-1), 138.8 
(C, d, J = 20 Hz, C-1’), 133.1 (CH), 133.0 (CH), 131.8 (CH, C-4’’), 131.8 (CH), 128.8 (CH, 
C-2’), 128.7 (CH), 127.4 (C, d, J = 90.6 Hz, C-1’’), 49.7 (CH, d, J = 110.6 Hz, C-2), 25.7 
(CH2), 25.6 (CH2), 22.9 (CH2), 22.1 (CH2); 31P NMR (161 MHz, CDCl3) δ 16.9 (s); LC-MS 
(m/z): Calculated C26H26OP+ [M+H]+: 385.1721, found: 385.1716. 
(2E)-1-(cyclohex-1-en-1-yl)oct-2-ene-1,7-dione (30a)  
Compound 30a was prepared following the same procedure for 
compounds 3a-e. Yellow oil (1.78 g, 81% yield). R.f 0.42 (EtOAc 1:1 
Hexane); FTIR (neat) Vmax: 2932, 2860, 1712, 1659, 1633, 1612, 1422, 
1354, 1285, 1202, 1157, 979, 732 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.89 (1H, m, 2’-
H), 6.85-6.75 (1H, m, 3-H), 6.65 (1H, m, 2-H), 2.50-2.42 (2H, m, 6-H), 2.31-2.19 (6H, 
m, 4,3’,6’-H), 2.13 (3H, s, 8-H), 1.81-1.70 (2H, m, 5-H), 1.68-1.57 (4H, m, 4’,5’-H); 13C 
NMR (100 MHz, CDCl3): δ 208.3 (CO, C-7), 191.1 (CO, C-1), 145.5 (CH, C-3), 140.2 (CH, 
C-2’), 139.8 (C, C-1’), 125.4 (CH, C-2), 42.7 (CH2, C-6), 31.7 (CH2, C-4), 30.0 (CH3, C-8), 
26.1 (CH2), 23.4 (CH2), 22.1 (CH2, C-5), 21.9 (CH2), 21.6 (CH2); LC-MS (m/z): Calculated 
C14H21O2+ [M+H]+: 221.1542, found: 221.1536. 
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(2E)-1-(cyclohex-1-en-1-yl)hept-2-ene-1,6-dione (30b) 
Compound 30b was prepared following the same procedure for 
compounds 3a-e where 5b is the appropriate aldehyde. Yellow oil 
(750 mg, 36% yield). R.f 0.39 (EtOAc 1:1 Hexane); FTIR (neat) Vmax: 
2930, 2860, 1713, 1659, 1633, 1612, 1422, 1364, 1204, 1160, 976, 
921, 794 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.88 (1H, s, 2’-H), 6.77 (1H, dt, J = 15.3, 6.6 
Hz, 3-H), 6.65 (1H, d, J = 15.3 Hz, 2-H), 2.61 (2H, t, J = 7.1 Hz, 5-H), 2.53-2.43 (2H, m, 
4-H), 2.29-2.22 (4H, m, 3’,6’-H), 2.15 (3H, s, 7-H), 1.66-1.58 (4H, m, 4’,5’-H); 13C NMR 
(100 MHz, CDCl3): δ 207.1 (CO, C-6), 191.1 (CO, C-1), 144.4 (CH, C-3), 140.4 (CH, C-2’), 
139.7 (C, C-1’), 125.6 (CH, C-2), 41.8 (CH2, C-5), 30.0 (CH3, C-7), 26.4 (CH2, C-4), 23.4 
(CH2), 22.1 (CH2), 21.9 (CH2), 21.6 (CH2); LC-MS (m/z): Calculated C13H19O2+ [M+H]+: 
207.1385, found: 207.1380. 
1-(cyclohex-1-en-1-yl)-2-[(2S,6S)-6-methylpiperidin-2-yl]ethanone (31a) 
Compound 31a was prepared following the same procedure for 
compounds 1f. Colourless oil (25mg, 45% yield). FTIR (neat) Vmax: 
2952, 2856, 1740, 1660, 1637, 1435, 1375, 1318, 1284, 1193, 1163, 
1122, 921, 773, 731 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.97-6.82 (1H, m, 2’-H), 3.13-
2.93 (1H, m, 2’’-H), 2.85 (1H, br s, 1’’-H), 2.77-2.71 (2H, m, 2-H), 2.70-2.61 (1H, m, 6’’-
H), 2.30-2.09 (4H, m), 1.79-1.67 (1H, m), 1.65-1.48 (6H, m), 1.45-1.29 (1H, m), 1.04 
(3H, d, J = 6.4 Hz, 1’’’-H), 1.27-0.99 (2H, m); 13C NMR (100 MHz, CDCl3): δ 200.5 (CO, 
C-1), 140.6 (CH, C-2’), 139.4 (C, C-1’), 53.1 (CH, C-2’’), 52.2 (CH, C-6’’), 43.6 (CH2, C-2), 
33.6 (CH2), 31.8 (CH2), 26.0 (CH2), 24.5 (CH2), 22.9 (CH2), 22.7 (CH3, C-1’’’), 21.8 (CH2), 
21.4 (CH2); LC-MS (m/z): Calculated C14H24NO+ [M+H]+: 222.1852, found: 222.1860. 
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(1S,3aR,5aS,9aS)-1-methyldecahydropyrrolo[1,2-a]quinolin-5(1H)-one (32a) 
 Compound 32a was prepared following the same procedure for 
compounds 1f. Colourless oil (13 mg, 26% yield). 1H NMR (400 MHz, 
o-C6D4Cl2) δ 3.48-3.37 (1H, m, 1-H), 2.68-2.55 (1H, m, 3a-H), 2.39 (1H, 
dd, J = 12.5, 3.2 Hz, 4-H), 2.16 (t, J = 12.5 Hz, 4-H), 2.09 (1H, td, J = 9.8, 3.1 Hz, 9a-H), 
1.99-1.91 (3H, m, 5a-H), 1.87-1.75 (1H, m), 1.71-1.59 (2H, m), 1.38-1.02 (7H, m), 0.70 
(3H, d, J = 6.9 Hz, 1’-H); 13C NMR (100 MHz, o-C6D4Cl2) δ 208.3 (CO, C-5), 60.6 (CH, C-
9a), 58.5 (CH, C-3a), 53.7 (CH, C-5a), 52.3 (CH, C-1), 48.1 (CH2, C-4), 31.8 (CH2), 30.3 
(CH2), 30.0 (CH2), 25.3 (CH2), 24.8 (CH2), 24.0 (CH2), 13.0 (CH3, C-1’). 
(1S,3aR,5aR,9aS)-1-methyldecahydropyrrolo[1,2-a]quinolin-5(1H)-one (32b) 
Compound 32b was prepared following the same procedure for 
compounds 1f. Colourless oil (10 mg, 20% yield). 1H NMR (400 MHz, 
CDCl3) δ 3.39-3.31 (1H, m, 9a-H), 2.99-2.89 (1H, m, 3a-H), 2.88-2.78 
(1H, m, 1-H), 2.78-2.73 (1H, m, 5a-H), 2.45 (1H, dd, J = 14.0, 3.4 Hz, 4-H), 2.32-2.23 
(2H, m, 4-H), 1.98-1.64 (5H, m), 1.53-1.36 (3H, m), 1.14 (3H, d, J = 6.0 Hz, 1’-H), 1.35-
0.96 (3H, m); 13C NMR (100 MHz, CDCl3): δ 210.9 (CO, C-5), 56.7 (CH, C-3a), 55.6 (CH, 
C-9a), 52.4 (CH, C-1), 49.6 (CH, C-5a), 47.9 (CH2, C-4), 31.1 (CH2), 29.6 (CH2), 25.0 
(CH2), 24.9 (CH2), 22.4 (CH2), 19.6 (CH2), 18.5 (CH3, C-1’). 
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4. Synthesis of Perhydrohistrionicotoxin Analogues 
4.1 Introduction  
When considering the design of potential novel drug candidates, the affinity towards 
the specific drug-binding site is a key factor.[100] Spiro-fused bicyclic ring systems 
containing quaternary sp3 carbons provide rigid 3D-motifs capable of enhanced 
selectivity in drug binding.[101] Interestingly, not many general synthetic methods 
towards the synthesis of 2-spiropiperidines have been developed to date.[102] 
Histrionicotoxins (HTXs) (33) are naturally occurring alkaloids, isolated from the skin 
of Colombian frogs (Dendrobates histrionicus) that contain a 2-spiropiperidine motif 
(Table 8).[103] Due to its unique structure and potent biological activity, as a very 
selective non-competitive antagonist of the nicotinic acetylcholine receptor,[104–106] 
numerous research groups have developed imaginative routes towards this molecule 
and related derivatives.[107–113]  
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Table 8: Structures of Histrionicotoxin alkaloids 
 
(HTX) R1 R2 
259A 
 
 
283A[113] 
 
 
285B 
 
 
287A 
 
 
perhydro[114] 
  
7-debutyl-
perhydro  
H 
 
The implementation of an IMAMR towards the synthesis of HTX products has 
previously been explored. Winterfeldt et al. synthesised perhydrohistrionicotoxin via 
a key IMAMR reaction. However, the reaction was not spontaneous and required the 
formation of a ketal to force the IMAMR (Scheme 39).[115] Godleski et al. then 
reported a Lewis acid-catalysed IMAMR of analogous non-cyclised amine 
intermediates.[116] Most recently, Robinson et al. have reported a shorter synthetic 
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route to the Winterfeldt amine via a cross-metathesis−hydrogenation during a 
formal synthesis of (-)-perhydrohistrionicotoxin. During this study, it was confirmed 
that the ketal formation is optimal for inducing the IMAMR (Scheme 39).[114] 
 
Scheme 39: Reported synthesis of (-)-perhydrohistrionicotoxin by Robinson et al.[114] 
4.2 Aims and objectives 
Herein we explore the TA-triggered IMAMR towards the synthesis of HTX derivatives. 
The proposed retrosynthetic analysis of the core HTX structure involves the oxidation 
of the chiral alcohol 33 followed by a retro-IMAMR to the comparable Winterfeldt 
amine 35 (Scheme 40). A synthetic route to compound 36 is planned and optimised. 
Then, investigation of the biocatalysed transamination reaction of 36 and their 
subsequent epimerisation are examined. 
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Scheme 40: Retrosynthetic analysis of the core structure of HTX  
 
4.3 Synthesis of keto-cyclohexanones 36a-e 
Suemune et al. reported the synthesis of compound 36a (R=H) in a two-step synthesis 
(Scheme 41).[117] This synthetic route consists of the addition of the Grignard reagent 
37 onto commercially available 3-ethoxy-2-cyclohexenone. Selective Wacker 
oxidation of the terminal alkene in 38a provides the ketoenone 36a. We applied the 
same strategy to generate the desired histrionicotoxin precursor 36a-e. The addition 
of the Grignard reagent 37 to 3-ethoxy-2-cyclohexenone produced target compound 
38a in 87% yield. For the Wacker oxidation, Suemune et al. reported the use of 0.5 
eq of PdCl2 and 4.0 eq of CuCl as co-catalyst, which provides a 76% yield.[117] In 
comparison, we found that, when 0.1 eq of PdCl2 and 2 eq of the CuCl, the reaction 
proceeded with full conversion and provided the target compound 36a in an 
increased 96% yield. 
89 
 
 
Scheme 41: Synthetic route to keto-cyclohexenones 36a-e 
A Baylis-Hillman reaction was employed to insert alkyl groups as substituents onto 
the -position of compound 38a. The alkylation reaction of 38a with MeI, using 
potassium tert-butoxide as base in THF, at 0 °C,[118] was unsuccessful (Table 9, entry 
1); however, the use of bromoethane as electrophile, under the same reaction 
conditions, provided 38c in a modest 33% yield (Table 9, entry 2). When the reaction 
with bromoethane was carried out at room temperature, an increased 56% yield of 
38c was obtained (Table 9, entry 3). At this optimal temperature, a change in the 
solvent of the reaction to diethyl ether provided 38c in 67% yield and a drastic 
decrease in side product formation, allowing for easier purification (Table 9, entry 4). 
The alkylation of 38a with bromopropane and bromobutane provided comparable 
yields for the synthesis of 38d,e (Table 9, entry 5 and 6). Wacker oxidation of 
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compounds 38c-e utilising the previously optimised conditions developed for the 
oxidation of 38a provided 36c-e in good yield (Scheme 41). 
Table 9: Baylis-Hillman Reaction Optimisationa 
Entry RX Solvent Temp (°C) Yield (%)b 
1 MeI THF 0 n.d 
2 EtBr THF 0 33 
3 EtBr THF 25 56 
4 EtBr Et2O 25 67 
5 n-PrBr Et2O 25 64 
6 n-BuBr Et2O 25 60 
a 1.5 eq tBuOK, 1.2 eq RX, 1 h. b Isolated yield after flash 
chromatography  
 
An alternative synthetic approach for the methyl substituted cyclohexanone 38b was 
developed, due to the Baylis-Hillman reaction proving ineffective with iodomethane. 
Thus, the commercially available 2-methyl-cyclohexan-1,3-dione was converted to 
39 in the presence of acid, in 72% yield (Scheme 42). The addition of 37 to compound 
39 provided 38b in 43% yield. Subsequent Wacker oxidation reaction of 38b, under 
the previously optimised conditions for the synthesis of 38a,c-e, provided our target 
compound 36b in 76% yield (24% overall yield from starting material 2-methyl-
cyclohexan-1,3-dione).   
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Scheme 42: Synthesis of 2-methyl-3-(4-oxopentyl)cyclohex-2-en-1-one (36b) 
 
4.4 Transamination of substrates 36a,c 
The transamination reaction of the unsubstituted keto enone 36a, under the 
conditions developed in section 2.4 (ATA113, PLP, HEPES, 2 eq IPA, 30 oC, 24 h) 
resulted in no conversion. We believe that the IMAMR at a disubstituted -position 
of the enone proceeds via a higher activation energy due to steric hindrance, 
hampering the equilibrium drive of our methodology. The use of the Codexis enzyme 
ATA 256 instead of ATA 113, allows the use of higher temperatures of the reaction 
(50 °C), which could potentially facilitate the desired IMAMR. Thus, the reaction of 
36a with ATA 256 at 50 °C, in the presence of two equivalent of IPA, provided, after 
three days, full conversion of starting material into the desired spirocyclic compound 
34a as a mixture of diastereomers (Scheme 43).  
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Scheme 43: Transamination of 36a for the synthesis of compound 34a 
The diastereomeric ratio (d.r.) of spirocycle 34a was determined to be 1:1 by analysis 
of the 1H NMR spectrum and GC-MS. Traditional epimerisation methods performed 
on these substrates were tested with limited success.[116] Stirring in MeOH at room 
temperature or at reflux, as previously described for 2,6-disubstituted piperidines 
(section 2.4), provided no change in d.e. and induced the degradation of spirocycle 
34a (Table 10, entry 1-2). The addition of sodium methoxide in methanol at room 
temperature had no effect in the diastereomeric ratio of the crude mixture (Table 
10, entry 3-4). Changing the solvent to CH3Cl or toluene yielded no epimerisation 
when sodium methoxide was employed at either room temperature or reflux 
conditions (Table 10, entries 5-8). Next, we examined two solid phase catalysts, silica 
gel and basic alumina, which provided no epimerisation (Table 10, entries 9 and 12). 
Fortunately, neutral alumina, at room temperature, provided a 3:1 mixture of 
diastereomers 34a (Table 10, entry 10). When the reaction with neutral alumina was 
carried out at higher temperature (50 oC) the diastereomeric ratio did not improve 
further than the previous 3:1 ratio (Table 10, entry 11).  
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Table 10: Epimerisation of spirocycle 34a 
 
Entry Solvent Additivea Temp (°C) d.r.b,c 
1 MeOH - 25 1:1 
2 MeOH - 65 1:1 
3 MeOH NaOMe 25 1:1 
4 MeOH NaOMe 65 1:1 
5 CH3Cl NaOMe 25 1:1 
6 CH3Cl NaOMe 40 1:1 
7 Tol NaOMe 25 1:1 
8 Tol NaOMe 110 1:1 
9 - Silica gel 25 1:1 
10 - Neutral alumina 25 3:1 
11 - Neutral alumina 50 3:1 
12 - Basic alumina 25 1:1 
a 2 eq. of additive. b D.r. determined by GC-MS. c D.r tested every 12 h until no 
change was observed. 
 
Attempted separation of the 3:1 mixture of diastereomers 34a on silica gel proved 
unsuccessful, as epimerisation (via a retro Michael reaction) occurred. For this 
reason, we attempted the reduction of the 3:1 mixture of diastereomers 34a with 
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NaBH4 and L-selectride. Although the reduction of the crude 34a (3:1 diastereomeric 
mixture) proceeded with full conversion to HTX 33a, separation of the potential four 
diastereomers by column chromatography was unsuccessful. Magnus et al. had 
reported that, when employing the bulky reducing agent L-selectride, the reduction 
proceeds with good selectivity.[119] In our case, this method provided two major 
isomers (identified by 1H NMR) (Scheme 44). In contrast, the use of the non-bulky 
(and therefore less selective) NaBH4 provided a 3:3:1:1 mixture of 33a. 
 
Scheme 44: Reduction of 34a with the reducing agents NaBH4 and L-selectride 
Investigations into the transamination reaction of the -ethyl ketocyclohexanone 
36c were also carried out. Unfortunately, the optimised conditions for the 
unsubstituted ketocyclohexanone 36a (ATA256, 50 oC, 72 h) proved to be ineffective. 
After two days, only two minor peaks representing the corresponding cyclised 
product 34c were present in the GC-MS analysis of a crude sample. In addition, an 
assumed non-cyclised product 35c was identified in the GC-MS chromatogram of the 
sample (Scheme 45). A standard work up of the reaction mixture (extraction with 
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EtOAc and concentration under reduced pressure) shifted the reaction towards the 
cyclised product 34c, providing a 3:1 mixture of isomers 34c, and non-cyclised 35c. 
The epimerisation of this 3:1 mixture of isomers 34c and 35c was attempted utilising 
neutral alumina. However, these conditions promoted a retro-Michael reaction and 
the reformation of non-cyclised product 35c as the only product. Standard work up 
of the non-cyclised 35c provides the 1:1 mixture of 35c and 34c (3:1 d.r.). Isolation of 
products 34c and/or 35c on silica gel proved unsuccessful.  
 
Scheme 45: Transamination of keto cyclohexanone 36c and epimerisation of 34c and 
35c 
Preliminary work on the transamination of 36b,d and e revealed similar behaviour to 
substrate 36c, with low conversions towards the desired spirocyclic systems 34b,d 
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and e. In addition, we observed that, as the alkyl chain length at the  position of the 
enone increased, the aza-Michael cyclisation became less favourable and the 
conversion of the reaction decreased.  
4.5 Conclusion and future work 
In conclusion, we have developed a practical methodology towards the synthesis of 
2-alkyl-3-(4-oxopentyl)cyclohex-2-en-1-one substrates 36a-e, by means of an 
optimised Baylis-Hillman reaction. The transamination reaction for the unsubstituted 
ketocyclohexanone 36a proceeded well, which is ascribed to the Michael product 
34a being stable in the reaction media. In this case, the IMAMR provided the 
expected thermodynamic driving force towards the formation of the desired cyclic 
product requiring no additional drive. Epimerisation of the diastereomeric mixture 
yielded a 3:1 d.r. of isomers, however, purification/separation of the two 
diastereomers proved unsuccessful. The selective reduction of the carbonyl offers a 
potential route to isolating spirocyclic compound 33a, but this reaction needs 
optimisation. Preparative (chiral) HPLC could also be employed for the separation of 
isomers.  
The transamination of 2-ethyl-3-(4-oxopentyl)cyclohex-2-en-1-one 36c under the 
previously optimised reaction conditions proved unsuccessful. This can be explained 
by the steric clash of the alkyl substituent with the piperidine ring, which induces a 
retro-Michael reaction, negating the possibility of the IMAMR driving the equilibrium 
towards the formation of the desired product 34c. The use of an excess of amine 
donor was also examined, however, it had negligible effect on the reaction 
equilibrium. We believe that future attempts at the transamination of 2-alkyl-3-(4-
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oxopentyl)cyclohex-2-en-1-one 36b-e should include an external method of driving 
the reaction equilibrium towards the formation of product (e.g. IPA removal system, 
o-xylylenediamine as the amine donor or use of a flow reactor). In addition, isolation 
of the Winterfeldt amines 34b-e[113] could offer a competitive route to non-natural 
derivatives of perhydrohistrionicotoxin.  
 
4.6 Experimental 
For general methods and materials, see experimental section 2.6. 
3-ethoxy-2-methylcyclohex-2-en-1-one (39)[120] 
To 2-methyl-1,3-cyclohexanedione (1.0 eq, 30.52 mmol, 3.85 g) 
dissolved in ethanol was added glacial acetic acid (1.0 eq, 30.52 
mmol, 1.75 mL) and MgSO4 (5.0 eq, 152.6 mmol, 18.36 g) and the mixture left to stir 
for 24 h at room temperature. The crude product was filtered, concentrated under 
reduced pressure and purified by column chromatography on silica gel (Et2O) to 
provide the title compound as a yellow oil (3.37 g, 72% yield). R.f 0.26 (Et2O); FTIR 
(neat) νmax (cm-1): 3411, 2938, 1732, 1647, 1617, 1197, 1116; 1H NMR (400 MHz, 
CDCl3): δ 4.05 (2H, q,  J = 7.2 Hz, 1’’-H), 2.54-2.52 (2H, m, 4-H), 2.34-2.31 (2H, m, 6-
H), 1.99-1.96 (2H, m, 5-H), 1.68 (3H, s, 1’-H), 1.37-1.33 (3H, t,  J = 5.3 Hz, 2’’-H); 13C 
NMR (100 MHz, CDCl3): δ 199.1 (CO, C-1), 171.6 (C, C-3), 115.0 (C, C-2), 63.5 (CH2, C-
1’’), 36.2 (CH2¸ C-6), 25.3 (CH2¸ C-4), 21.0 (CH2¸ C-5), 15.3 (CH3¸ C-2’’), 7.4 (CH2¸ C-1’); 
LC-MS (m/z): calculated C9H15O2 [M+H]+: 155.1067, found: 155.0994. 
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3-(4-Pentenyl)cyclohex-2-en-1-one (38a)[117] 
To a solution of Grignard reagent prepared from 5-bromo-1-
pentene (1.3 eq, 26 mmol, 3.08 mL) and magnesium metal (1.2 
eq, 24 mmol, 564 mg) in diethyl ether (25 mL) was added 3-
ethoxy-2-cyclohexenone (1 eq, 20 mmol, 2.91 mL) in diethyl ether (20 mL) at room 
temperature and stirred for 30 min. The reaction mixture was quenched with sat. 
NH4Cl solution (50 mL). The aqueous mixture was extracted with EtOAc (3 x 20 mL), 
the organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude material was purified 
by column chromatography on silica gel (EtOAc 1:9 hexane) to provide the title 
compound as a colourless oil (2.84 g, 87% yield). R.f 0.38 (EtOAc 3:7 Hexane); FTIR 
(neat) Vmax: 2930, 1665, 1624, 1428, 1251, 909, 888 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 5.87 (1H, s, 2-H), 5.84-5.71 (1H, m, 4’-H), 5.05-4.95 (2H, m, 5’-H), 2.35 (2H, t, J = 6.6 
Hz, 6-H), 2.28 (2H, t, J = 6.0 Hz, 4-H), 2.21 (2H, t, J = 7.8 Hz, 1’-H), 2.11-2.03 (2H, m, 
3’-H), 2.02-1.94 (2H, m, 5-H), 1.64-1.55 (2H, m, 2’-H); 13C NMR (100 MHz, CDCl3): δ 
199.9 (CO, C-1), 166.2 (C, C-3), 137.8 (CH, C-4’), 125.8 (CH, C-2), 115.3 (CH2¸ C-5’), 
37.3 (2CH2¸ C-6,1’), 33.2 (CH2¸ C-3’), 29.7 (CH2¸ C-4), 26.0 (CH2¸ C-2’), 22.7 (CH2¸ C-5); 
LC-MS (m/z): calculated C11H17O [M+H]+: 165.1279, found: 165.1273. 
2-methyl-3-(pent-4-en-1-yl)cyclohex-2-en-1-one (38b)[121] 
 Compound 38b was prepared following the same procedure for 
compounds 38a, starting from compound 39. The resulting 
crude material was purified by column chromatography (EtO2 4:6 hexane) to provide 
a yellow oil (845 mg, 43% yield); Rf 0.31 (4:6 EtO2 4:6 Hexane); FTIR (neat) νmax (cm-1): 
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3310, 3076, 2930, 2866, 1673, 1627, 1191, 1083, 911; 1H NMR (400 MHz, CDCl3): δ 
5.91-5.69 (1H, m, 4’’-H), 5.12-4.90 (2H, m, 5’’-H), 2.37 (2H, t, J = 6.8 Hz, 4-H), 2.35-
2.29 (2H, m, 6-H), 2.27-2.20 (2H, m, 1’’-H), 2.14-2.03 (2H, m, 3’’-H), 1.97-1.86 (2H, m, 
5-H), 1.75 (3H, s, 1’-H), 1.65-1.45 (2H, m, 2’’-H); 13C NMR (100 MHz, CDCl3): δ 199.5 
(CO, C-1), 158.8 (C, C-3), 138.0 (CH, C-4’’), 130.9 (C, C-2), 115.2 (CH2, C-5’’), 37.7 (CH2, 
C-4), 34.7 (CH2, C-1’’), 33.7 (CH2, C-3’’), 30.8 (CH2, C-6), 26.6 (CH2, C-2’’), 22.5 (CH2, C-
5), 10.6 (CH3, C-1’); LC-MS (m/z): calculated C12H19O [M+H]+:  179.1430, found: 
179.1432. 
General Procedure for the alkylation of 38a 
To 3-(4-pentenyl)cyclohex-2-en-1-one (38a) (1 eq, 3.0 mmol, 493 mg) in dry Et2O (12 
mL) was added tBuOK (1.5 eq, 4.5 mmol, 505 mg) and the mixture stirred for 15 min. 
The appropriate alkyl halide (1.2 eq, 3.6 mmol) was then added dropwise and the 
reaction stirred for 1 h. The reaction mixture was quenched with sat. NH4Cl solution 
(20 mL) and extracted with EtOAc (3 x 20 mL), the organic extracts were combined, 
washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude material was purified by column chromatography on 
silica gel (EtOAc 1:9 hexane) to provide the title compounds 38c-e. 
2-ethyl-3-(pent-4-en-1-yl)cyclohex-2-en-1-one (38c) 
Yellow oil (510 mg, 67% yield). R.f 0.33 (Et2O 3:7 hexane); FTIR 
(neat) Vmax: 2931, 2868, 1660, 1620, 1456, 1431, 1362, 909 cm-
1; 1H NMR (400 MHz, CDCl3): δ 5.94-5.68 (1H, m, 4’’-H), 5.14-4.86 (2H, m, 5’’-H), 2.41-
2.20 (8H, m, 4, 6, 1’, 1’’-H), 2.17-2.04 (2H, m, 3’’-H), 1.97-1.85 (2H, m, 5-H), 1.62-1.50 
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(2H, m, 2’’-H), 0.93 (3H, t, J = 7.6 Hz, 2’-H); 13C NMR (100 MHz, CDCl3): δ 199.1 (CO, 
C-1), 158.4 (C, C-3), 138.0 (CH, C-4’’), 137.0 (C, C-2), 115.2 (CH2¸ C-5’’), 38.1 (CH2¸ C-
6), 34.2 (CH2¸ C-1’’), 33.8 (CH2¸,C-3’’), 30.6 (CH2¸ C-4), 27.2 (CH2¸ C-2’’), 22.6 (CH2¸ C-
5), 18.3 (CH2¸ C-1’), 14.2 (CH3¸ C-2’); LC-MS (m/z): calculated C13H21O [M+H]+: 
193.1587, found: 193.1587. 
3-(pent-4-en-1-yl)-2-propylcyclohex-2-en-1-one (38d) 
Yellow oil (264 mg, 64% yield). R.f 0.32 (EtO2 3:7 hexane); FTIR 
(neat) Vmax: 2956, 2930, 2867, 1661, 1619, 1456, 1365, 1188, 
1108, 910 cm-1; 1H NMR (400 MHz, CDCl3): δ 5.92-5.69 (1H, m, 4’’-H), 5.13-4.91 (2H, 
m, 5’’-H), 2.39-2.36 (2H, t, J = 6.6 Hz, 6-H), 2.31 (2H, t, J = 6.0 Hz, 4-H), 2.27-2.18 (4H, 
m, 1’,1’’-H), 2.14-2.05 (2H, m, 3’’-H), 1.95-1.85 (2H, m, 5-H), 1.61-1.49 (2H, m, 2’’-H), 
1.42-1.20 (2H, m, 2’-H), 0.89 (3H, t, J = 7.3 Hz, 3’-H); 13C NMR (100 MHz, CDCl3): δ 2; 
13C NMR (100 MHz, CDCl3): δ 199.2 (CO, C-1), 158.7 (C, C-3), 138.0 (CH, C-4’’), 135.6 
(C, C-2), 115.2 (CH2¸ C-5’’), 38.1 (CH2¸ C-6), 34.4 (CH2¸ C-1’’), 33.8 (CH2¸ C-3’’), 30.6 
(CH2¸ C-4), 27.2 (CH2¸C-2’’), 27.1 (CH2¸ C-1’), 22.9 (CH2¸ C-2’), 22.6 (CH2¸ C-5), 14.3 
(CH3¸ C-3’); LC-MS (m/z): calculated C14H23O [M+H]+: 207.1749, found: 207.1744. 
2-butyl-3-(pent-4-en-1-yl)cyclohex-2-en-1-one (38e) 
Yellow oil (525 mg, 60% yield). R.f 0.35 (Et2O 3:7 hexane); FTIR 
(neat) Vmax: 2954, 2930, 2861, 1663, 1456, 1356, 1187, 910 cm-
1; 1H NMR (400 MHz, CDCl3) δ 5.87-5.75 (1H, m, 4’’-H), 5.09-4.97 (2H, m, 5’’-H), 2.36 
(2H, t, J = 6.6 Hz, 6-H), 2.33-2.28 (2H, m, 4-H), 2.26-2.22 (4H, m, 2’,1’’-H), 2.13-2.08 
(2H, m, 3’’-H), 1.96-1.86 (2H, m, 5-H), 1.62-1.50 (2H, m, 2’’-H), 1.38-1.22 (4H, m, 1’,3’-
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H), 0.89 (3H, t, J = 7.1 Hz, 4’-H); 13C NMR (100 MHz, CDCl3): δ 199.2 (CO, C-1), 158.5 
(C, C-3), 138.0 (CH, C-4’’), 135.8 (C, C-2), 115.2 (CH2, C-5’’), 38.1 (CH2, C-6), 34.3 (CH2, 
C-1’’), 33.8 (CH2, C-3’’), 31.9 (CH2, C-1’), 30.6 (CH2, C-4), 27.2 (CH2, C-2’’), 24.9 (CH2, 
C-2’), 23.0 (CH2, C-3’), 22.6 (CH2, C-5), 14.0 (CH3, C-4’); LC-MS (m/z): calculated 
C15H25O [M+H]+: 221.1905, found: 221.1900. 
General Procedure for Wacker Oxidation of (38a-e) 
To PdCl2 (50 mg, 0.60 mmol) and CuCl (1.19 g, 12.0 mmol) in DMF (20 mL) and water 
(5 mL) that had been stirred under an O2 atmosphere for 1 h was added a solution of 
38a-e (985 mg, 6.00 mmol) in DMF (5 mL) drop wise and the mixture stirred for 30 
mins. The reaction mixture was quenched with NH4Cl (20 mL) and ammonium 
hydroxide solution (20 mL) and extracted with diethyl ether (3 x 40 mL). The 
combined organic extracts were then washed with brine (2 x 60 mL) and dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude material was 
purified by column chromatography on silica gel (EtOAc 3:7 hexane) to provide the 
isolated compounds 36a-e. 
3-(4-oxopentyl)cyclohex-2-en-1-one (36a)[117] 
Yellow oil (527 mg, 96% yield). R.f 0.18 (EtOAc 1:1 hexane); FTIR 
(neat) Vmax 2928, 1712, 1662, 1623, 1367, 1252, 887, 729 cm-1; 
1H NMR (400 MHz, CDCl3): δ 5.83 (1H, s, 2-H), 2.44 (2H, t, J = 7.1 Hz, 3’-H), 2.33 (2H, 
t, J = 6.6 Hz, 6-H), 2.26 (2H, t, J = 6.2 Hz, 4-H), 2.19 (2H, t, J = 7.6 Hz, 1’-H), 2.12 (3H, s, 
5’-H), 2.00-1.91 (2H, m, 5-H), 1.81-1.72 (2H, m, 2’-H); 13C NMR (100 MHz, CDCl3): δ 
208.0 (CO, C-4’), 199.8 (CO, C-1), 165.4 (C, C-3), 125.9 (CH, C-2), 42.5 (CH2¸ C-3’), 37.2 
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(CH2¸ C-6), 37.1 (CH2¸ C-1’), 30.0 (CH3¸ C-5’), 29.4 (CH2¸ C-4), 22.6 (CH2¸ C-5), 20.5 (CH2¸ 
C-2’); LC-MS (m/z): calculated C11H17O2 [M+H]+: 181.1229, found: 181.1220. 
2-methyl-3-(4-oxopentyl)cyclohex-2-en-1-one (36b) 
Yellow oil (703 mg, 76% yield); FTIR (neat) νmax (cm-1): 3406, 
2941, 1712, 1658, 1624, 1410, 1357, 1170, 1085; 1H NMR (400 
MHz, CDCl3): δ 2.46 (2H, t, J = 7.1 Hz, 3’’-H), 2.37 (2H, t, J = 6.6 Hz, 4-H), 2.34-2.28 (2H, 
m, 6-H), 2.22 (2H, t, J = 8.0 Hz, 1’’H), 2.14 (3H, s, 5’’-H), 1.96-1.86 (2H, m, 5-H), 1.75 
(3H, s, 1’-H), 1.82-1.67 (2H, m, 2’’-H); 13C NMR (100 MHz, CDCl3): δ 208.1 (CO, C-4’’), 
199.5 (CO, C-1), 157.9 (C, C-3), 131.3 (C, C-2), 42.9 (CH2, C-3’’), 37.7 (CH2, C-4), 34.3 
(CH2, C-1’’), 30.6 (CH2, C-6), 30.0 (CH3, C-5’’), 22.4 (CH2, C-6), 21.2 (CH2, C-2’’), 10.6 
(CH3, C-1’); LC-MS (m/z): calculated C12H19O2 [M+H]+:  195.1380, found: 195.1384. 
2-ethyl-3-(4-oxopentyl)cyclohex-2-en-1-one (36c) 
Yellow oil (458 mg, 83% yield). R.f 0.34 (EtOAc 1:1 hexane); FTIR 
(neat) Vmax 2933, 2871, 1713, 1657, 1620, 1362, 1168, 1102 cm-
1; 1H NMR (400 MHz, CDCl3): δ 2.48 (2H, t, J = 7.1 Hz, 3’’-H), 2.39-2.19 (8H, m, 
4,6,1’,1’’-H), 2.15 (3H, s, 5’’-H), 1.96-1.85 (2H, m, 5-H), 1.80-1.67 (2H, m, 2’’-H), 0.92 
(3H, t, J = 7.6 Hz, 2’-H); 13C NMR (100 MHz, CDCl3): δ 208.1 (CO, C-4’’), 199.0 (CO, C-
1), 157.4 (C, C-3), 137.4 (C, C-2), 43.1 (CH2¸ C-3’’), 38.1 (CH2¸ C-6), 33.9 (CH2¸ C-1’’), 
30.4 (CH2¸ C-4), 30.0 (CH3¸ C-5’’), 22.5 (CH2¸ C-5), 21.7 (CH2¸ C-2’’), 18.3 (CH2¸ C-1’), 
14.2 (CH3¸ C-2’); LC-MS (m/z): calculated C13H21O2 [M+H]+: 209.1536, found: 
209.1536. 
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3-(4-oxopentyl)-2-propylcyclohex-2-en-1-one (36d) 
Yellow oil (239 mg, 84% yield). R.f 0.38 (EtOAc 1:1 hexane); FTIR 
(neat) Vmax 2956, 2869, 1713, 1658, 1619, 1364, 1169, 1108, 731 
cm-1; 1H NMR (400 MHz, CDCl3) δ 2.48 (2H, t, J = 7.2 Hz, 3’’-H), 2.36 (2H, m, 6-H), 2.32 
(2H, m, 4-H), 2.26-2.18 (4H, m, 1’,1’’-H), 2.15 (3H, s, 5’’-H), 1.94-1.87 (2H, m, 5-H), 
1.77-1.70 (2H, m, 2’’-H), 1.33-1.25 (2H, m, 2’-H), 0.89 (3H, t, J = 7.2 Hz, 3’-H); 13C NMR 
(100 MHz, CDCl3): δ 208.1 (CO, C-4’’), 199.2 (CO, C-1), 157.7 (C, C-3), 136.0 (C, C-2), 
43.1 (CH2, C-3’’), 38.1 (CH2, C-6), 34.0 (CH2, C-1’’), 30.4 (CH2, C-4), 30.0 (CH3, C-5’’), 
27.1 (CH2, C-1’), 22.9 (CH2, C-2’), 22.5 (CH2, C-5), 21.7 (CH2, C-2’’), 14.3 (CH3, C-3’); LC-
MS (m/z): calculated C14H23O2 [M+H]+: 223.1698, found: 223.1693. 
2-butyl-3-(4-oxopentyl)cyclohex-2-en-1-one (36e) 
Orange oil (447 mg, 79% yield). R.f 0.41 (EtOAc 1:1 hexane); FTIR 
(neat) Vmax 2953, 2930, 2869, 1713, 1660, 1364, 1164, 1112, 947 
cm-1; 1H NMR (400 MHz, CDCl3) δ 2.47 (2H, t, J = 7.1 Hz, 3’’-H), 2.36 (2H, t, J = 6.9 Hz, 
6-H), 2.31 (2H, t, J = 6.0 Hz, 4-H), 2.28-2.18 (4H, m, 1’,1’’-H), 2.15 (3H, s, 5’’-H), 1.93-
1.87 (2H, m, 5-H), 1.79-1.65 (2H, m, 2’’-H), 1.35-1.20 (4H, m, 2’,3’H), 0.88 (3H, t, J = 
7.1 Hz, 4’-H); 13C NMR (100 MHz, CDCl3): δ 208.0 (CO, C-4’’), 199.2 (CO, C-1), 157.5 
(C, C-3), 136.2 (C, C-2), 43.1 (CH2, C-3’’), 38.1 (CH2, C-6), 34.0 (CH2, C-1’’), 31.9 (CH2, 
C-1’), 30.4 (CH2, C-4), 30.0 (CH3, C-5’’), 24.9 (CH2, C-2’), 22.9 (CH2, C-3’), 22.5 (CH2, C-
5), 21.7 (CH2, C-2’’), 14.0 (CH3, C-4’); LC-MS (m/z): calculated C15H25O2 [M+H]+: 
237.1855, found: 237.1849. 
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(2S)-2-methyl-1-azaspiro[5.5]undecan-8-one (34a) 
Compound 34a was prepared following the same procedure for 
compounds 1f. Pale yellow oil (38 mg, 84% yield). 1H NMR (400 MHz, 
CDCl3) δ 2.91-2.78 (0.5H, m, 2-H), 2.78-2.64 (0.5H, m, 2-H), 2.54 (1H, 
s), 2.39-2.16 (3H, m), 2.16-1.79 (2H, m), 1.78-1.69 (1H, m), 1.69-1.46 (m, 6H), 1.28-
0.77 (m, 6H) 13C NMR (400 MHz, CDCl3) δ 211.1 (CO, C-8), 57.1, 56.9, 56.8, 56.7, 48.4, 
45.7, 45.5, 41.2, 41.0, 40.0, 36.1, 35.6, 35.3, 34.5, 34.4, 30.1, 23.1, 21.0, 20.7, 20.6, 
20.2, 20.0. 
  
105 
 
5. References 
[1] M. F. Roberts, M. Wink, Eds. , Alkaloids Biochemistry, Ecology, and Medicinal 
Applications, Springer US, 1998. 
[2] E. Fattorusso, O. Taglialatela-Scafati, Eds. , Modern Alkaloids: Structure, 
Isolation, Synthesis, and Biology, Wiley, New York, 2007. 
[3] A. HARVEY, Drug Discov. Today 2008, 13, 894–901. 
[4] I. Paterson, E. A. Anderson, Science  2005, 310, 451–453. 
[5] E. Vitaku, D. T. Smith, J. T. Njardarson, J. Med. Chem. 2014, 57, 10257–10274. 
[6] A. Walji, D. MacMillan, Synlett 2007, 1477–1489. 
[7] M. B. Smith, J. March, March’s Advanced Organic Chemistry, John Wiley & 
Sons, Inc., Hoboken, NJ, USA, 2006. 
[8] W. Li, X. Zhang, Eds. , Stereoselective Formation of Amines, Springer Berlin 
Heidelberg, Berlin, Heidelberg, 2014. 
[9] H.-U. Blaser, H.-P. Buser, H.-P. Jalett, B. Pugin, F. Spindler, Synlett 1999, 867–
868. 
[10] Y. Chi, Y.-G. Zhou, X. Zhang, J. Org. Chem. 2003, 68, 4120–4122. 
[11] V. I. Tararov, R. Kadyrov, A. Börner, T. H. Riermeier, Chem. Commun. 2000, 
1867–1868. 
[12] R. Kadyrov, T. H. Riermeier, U. Dingerdissen, V. Tararov, A. Börner, J. Org. 
Chem. 2003, 68, 4067–4070. 
106 
 
[13] Y. Hsiao, N. R. Rivera, T. Rosner, S. W. Krska, E. Njolito, F. Wang, Y. Sun, J. D. 
Armstrong, E. J. J. Grabowski, R. D. Tillyer, F. Spindler, C. Malan, J. Am. Chem. 
Soc. 2004, 126, 9918–9919. 
[14] T. Bunlaksananusorn, F. Rampf, Synlett 2005, 2682–2684. 
[15] D. Steinhuebel, Y. Sun, K. Matsumura, N. Sayo, T. Saito, J. Am. Chem. Soc. 2009, 
131, 11316–11317. 
[16] R. I. Storer, D. E. Carrera, Y. Ni, D. W. C. MacMillan, J. Am. Chem. Soc. 2006, 
128, 84–86. 
[17] S. Hoffmann, M. Nicoletti, B. List, J. Am. Chem. Soc. 2006, 128, 13074–13075. 
[18] C. Li, C. Wang, B. Villa-Marcos, J. Xiao, J. Am. Chem. Soc. 2008, 130, 14450–
14451. 
[19] W. Tang, S. Johnston, J. A. Iggo, N. G. Berry, M. Phelan, L. Lian, J. Bacsa, J. Xiao, 
Angew. Chem. Int. Ed. 2013, 52, 1668–1672. 
[20] C. Li, B. Villa-Marcos, J. Xiao, J. Am. Chem. Soc. 2009, 131, 6967–6969. 
[21] L. Rubio-Pérez, F. J. Pérez-Flores, P. Sharma, L. Velasco, A. Cabrera, Org. Lett. 
2009, 11, 265–268. 
[22] S. M. Changi, T. Yokozawa, T. Yamamoto, H. Nakajima, M. C. Embry, R. Vaid, C. 
V. Luciani, S.-W. Wong, M. Johnson, E. D. Moher, React. Chem. Eng. 2017, 2, 
720–739. 
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